SEARCH
Search Details
Hasegawa Yuta
| Hokkaido University Hospital Internal Medicine | Assistant Professor |
Researcher basic information
■ Degree■ URL
researchmap URLホームページURL■ Various IDs
Researcher number
- 20923733
Research activity information
■ Awards- Dec. 2024, 令和6年度フラテ研究奨励賞
- 2023, 日本白血病研究基金
臨床医学特別賞 - 2022, 日本血液学会奨励賞
- Sep. 2014, International society of Hematology, International society of Hematology XXXV world congress travel award
Risk factor of Central nervous system for patients with diffuse large B-cell lymphoma in post-Ritximub era
Yuta Hasegawa
- The impact of female-to-male allogeneic hematopoietic cell transplantation on survival outcomes varies by recipient age.
Kosuke Takano; Masaharu Tamaki; Yoshitaka Inoue; Shunto Kawamura; Seitaro Terakura; Dai Keino; Shinichi Kako; Shin-Ichiro Fujiwara; Noriko Doki; Tetsuya Nishida; Yuta Hasegawa; Noboru Asada; Masashi Sawa; Masatsugu Tanaka; Naoyuki Uchida; Nobuhiro Hiramoto; Hirohisa Nakamae; Koji Kawamura; Takahiro Fukuda; Marie Ohbiki; Yoshiko Atsuta; Yoshinobu Kanda; Kimikazu Yakushijin; Hideki Nakasone
Transplantation and cellular therapy, 27 May 2026, [International Magazine]
English, Scientific journal, BACKGROUND: Sex-mismatched allogeneic hematopoietic cell transplantation (allo-HCT), particularly with female donors and male recipients (FtoM), is known to be associated with an increased risk of chronic graft-versus-host disease (GVHD) and non-relapse mortality (NRM). This adverse effect of FtoM allo-HCT is considered to result from allo-immunity against Y-chromosome antigens. However, it has not been elucidated whether the adverse impact of FtoM allo-HCT varies by recipient age. OBJECTIVE: This study aims to examine the effect of sex-mismatch on clinical outcomes in allo-HCT from human leukocyte antigen (HLA)-matched donors, stratified by recipient age group. STUDY DESIGN: Using a Japanese transplantation registry database, we analyzed 10392 patients (n = 2169, 2573, and 5650 in FtoM, MtoF, and sex-matched allo-HCT, respectively) with standard-risk hematological malignancies who had undergone their first allo-HCT from HLA-matched related or unrelated donors without in vivo T-cell depletion between 2008 and 2022. The impact of sex-mismatch on clinical outcomes was separately assessed by recipient age groups: ≤ 15, 16-39, and ≥ 40 years. The primary endpoint was overall survival (OS). Secondary endpoints included disease-free survival, NRM, and the cumulative incidences of acute and chronic GVHD. RESULTS: In recipients aged ≥ 40 years, OS and NRM at 5 years post-HCT were significantly worse in the FtoM group compared with the MtoF and sex-matched groups (5-year OS 49.5% vs 59.6% vs 57.1%, P < 0.001; 5-year NRM 27.9% vs 21.9% vs 23.0%, P < 0.001), while no differences were observed among the FtoM, MtoF, and sex-matched groups in recipients aged ≤ 15 years or 16-39 years. Multivariate analyses confirmed that FtoM allo-HCT was significantly associated with increased mortality only in recipients aged ≥ 40 years (hazard ratio [HR] for OS 1.31, P < 0.001; HR for NRM 1.44, P < 0.001). The FtoM group in recipients aged ≥ 40 years frequently experienced fatal infection and fatal non-infectious pulmonary complications. In addition, we confirmed that the adverse effect of FtoM allo-HCT on OS similarly appeared only in recipients aged ≥ 40 years in both sub-cohorts divided by a median of donor age (40 years). CONCLUSION: The adverse impact of FtoM allo-HCT on survival outcomes differed according to recipient age. Our findings suggest that female donors should be avoided, especially in older male recipients undergoing allo-HCT. - Bidirectional associations between bacteraemia and cytomegalovirus infection after allogeneic haematopoietic cell transplantation: Japanese Society for Transplantation and Cellular Therapy Transplant Complications Working Group.
Shun-Ichi Kimura; Kazuki Yoshimura; Hideki Nakasone; Hiroki Hosoi; Kazuhiro Ishikawa; Naoyuki Uchida; Noriko Doki; Tetsuya Nishida; Yuta Hasegawa; Masatsugu Tanaka; Satoshi Yoshihara; Tetsuya Eto; Hirohisa Nakamae; Masako Toyosaki; Noboru Asada; Koji Kawamura; Takahiro Fukuda; Ken Tabuchi; Yoshiko Atsuta; Yoshinobu Kanda; Kimikazu Yakushijin
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 13 May 2026, [International Magazine]
English, Scientific journal, OBJECTIVES: Bacteraemia and cytomegalovirus (CMV) infection are major infectious complications after allogeneic haematopoietic cell transplantation (HCT). However, their bidirectional relationship, particularly in the setting of letermovir (LTV) prophylaxis, remains unclear. We investigated the bidirectional associations between bacteraemia and CMV infection and their impact on transplantation outcomes. We also evaluated the effect of LTV prophylaxis on these associations. METHODS: Using a nationwide Japanese transplant registry database, we analysed 23,841 patients who underwent their first allogeneic HCT between 2008 and 2022. Multivariable Cox proportional hazards models with time-dependent covariates were used to evaluate bidirectional associations between bacteraemia and clinically significant CMV infection (csCMVi). RESULTS: csCMVi was associated with an increased risk of subsequent bacteraemia (adjusted hazard ratio [aHR], 1.48; 95% CI, 1.33-1.64), with a stronger association among patients in the LTV group (aHR, 2.59; 95% CI, 1.87-3.60) than among those in the no-LTV group (aHR, 1.30; 95% CI, 1.16-1.46). Conversely, bacteraemia was modestly associated with an increased risk of csCMVi overall (aHR, 1.06; 95% CI, 1.01-1.11), but this association was observed only in the LTV group (aHR, 1.61; 95% CI, 1.40-1.85). These bidirectional associations were consistent in the LTV era and in patients without grade II-IV acute graft-versus-host disease. The findings were robust in sensitivity analyses, including landmark and propensity score-matched analyses. In propensity score-matched cohorts, both bacteraemia and csCMVi were associated with higher nonrelapse mortality (NRM; defined as death without relapse of the underlying malignancy) and inferior overall survival (OS), regardless of LTV use. CONCLUSIONS: Bacteraemia and csCMVi were bidirectionally associated after allogeneic HCT, particularly in the LTV group. Both bacteraemia and csCMVi were consistently associated with higher NRM and inferior OS, regardless of LTV prophylaxis. These findings highlight the need for integrated infection management strategies, particularly in the LTV era. - The role of HLA transcription in unrelated hematopoietic cell transplantation.
Satoko Morishima; Takashi Shiina; Fumihiro Azuma; Shohei Tomori; Noriko Doki; Tetsuya Nishida; Takahiro Fukuda; Tetsuya Eto; Keisuke Kataoka; Yuta Hasegawa; Masatsugu Tanaka; Shuichi Ota; Satoru Takada; Yuta Katayama; Naoyuki Uchida; Hirohisa Nakamae; Yoshinobu Kanda; Nobuhiro Hiramoto; Junya Kanda; Makoto Onizuka; Tatsuo Ichinohe; Yoshiko Atsuta; Yasuo Morishima; Makoto Murata
Blood advances, 10, 8, 2687, 2697, 28 Apr. 2026, [Peer-reviewed], [International Magazine]
English, Scientific journal, Expression levels of HLA are associated with susceptibility to various diseases and outcomes after allogeneic hematopoietic cell transplantation (HCT). However, there has been no comprehensive analysis of the effect of the expression levels of the HLA-A, -B, -C, and -DRB1 alleles in unrelated HCT (UR-HCT). Using the capture RNA-sequencing method, we analyzed the gene expression of HLA alleles in 443 healthy donors and determined allele-specific transcription (AST) levels. We assigned median AST (M-AST) levels to HLA typing data of patients who received a transplant from unrelated donors matched for HLA-A, -B, -C, and -DRB1 alleles, using transplant registry data. All 6084 patients were divided into low, middle, and high tertile groups according to the distribution of the sum of the 2 alleles of the M-AST level for each HLA locus and the sum of the 8 alleles of the M-AST level for all 4 loci. The risk of grade 2 to 4 acute graft-versus-host disease was significantly higher in the middle group (hazard ratio [HR], 1.11; P = .044) and high group (HR, 1.20; P< .001) than in the low group for the sum of the HLA-A, -B, -C, and -DRB1 loci. Similar results were observed at the HLA-A, -B, -C, and -DRB1 loci. Higher transcription levels were also associated with a lower risk of relapse at the HLA-B, -C, and -DRB1 loci. Our data suggest that high transcription levels of patient and/or donor HLA may evoke strong alloimmune responses and affect UR-HCT outcomes. - Impact of
CD34 + cell dose on outcomes of related allogeneicPBSCT in adultAML patients
Yusuke Toda; Tomoyasu Jo; Yasuyuki Arai; Kaito Harada; Masamitsu Yanada; Takahiro Fukuda; Satoshi Yoshihara; Noriko Doki; Naoyuki Uchida; Yasuo Mori; Yuta Hasegawa; Yukio Kondo; Toshiro Kawakita; Tetsuya Eto; Tetsuya Nishida; Masatsugu Tanaka; Makoto Onizuka; Katsuhiro Shono; Masayuki Hino; Tatsuo Ichinohe; Yoshiko Atsuta; Takaaki Konuma
British Journal of Haematology, Wiley, 28 Apr. 2026
Scientific journal, Summary
CD34 + cell dose is believed to impact the outcomes of allogeneic peripheral blood stem cell transplantation (PBSCT), yet the optimal dose remains unclear. We retrospectively reviewed 2407 adult patients with acute myeloid leukaemia who underwent their first related PBSCT between 2000 and 2019. The median infused CD34 + cell dose was 3.67 × 10 6 /kg. Patients were divided into three groups based on infused CD34 + cell dose: low (1.0–2.0 × 10 6 /kg), intermediate (2.0–4.0 × 10 6 /kg) and high (4.0–10.0 × 10 6 /kg) groups. The 5‐year overall survival rates were 37.2%, 40.2% and 37.4% in the low, intermediate and high groups respectively ( p = 0.176). Although the high‐group patients experienced faster neutrophil engraftment, cumulative incidences of infection and primary engraftment failure were comparable across groups. Platelet engraftment was significantly delayed in the low group, with 21.7% failing to engraft at day 100, compared to 14.6% and 13.4% in the intermediate and high groups ( p < 0.001). Furthermore, the incidence of secondary graft failure was significantly higher in the low group. In conclusion, a CD34 + cell dose >2.0 × 10 6 /kg improves platelet engraftment and reduces the risk of secondary graft failure but does not confer additional long‐term benefits. - Perioperative pharmacokinetics of lenacapavir during massive hemorrhage in a patient with hemophilia a undergoing liver transplantation.
Tomoyuki Endo; Yuki Tazawa; Toshihiro Matsukawa; Yuta Hasegawa; Ryoichi Goto; Tsuyoshi Shimamura; Hajime Matsushima; Takanobu Hara; Akihiko Soyama; Takanori Teshima; Susumu Eguchi
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 32, 6, 102980, 102980, 27 Apr. 2026, [International Magazine]
English, Scientific journal, Lenacapavir (LEN) is a long-acting HIV-1 capsid inhibitor administered subcutaneously every six months; however, its pharmacokinetic behavior during massive hemorrhage is unknown. We report a man in his 60s with multidrug-resistant HIV-1 infection and severe hemophilia A who underwent living-donor liver transplantation for HCV-related hepatocellular carcinoma. After a 2-week oral loading phase, LEN (927 mg) was administered four weeks before surgery. Liver transplantation was performed with intraoperative blood loss of 7046 g, approximately 1.5 times the estimated circulating blood volume. Despite this massive hemorrhagic stress, plasma LEN concentrations were 59.9 ng/mL on the day of surgery and 57.3 ng/mL on postoperative day 1, showing minimal change without additional dosing. Twenty-four weeks after the first injection, immediately before the second scheduled dose, plasma LEN concentration remained adequate at 80.8 ng/mL. HIV-1 RNA remained suppressed below 20 copies/mL throughout the clinical course. To our knowledge, this is the first report describing perioperative LEN pharmacokinetics during massive blood loss. These findings indicate that LEN exposure may remain stable despite substantial intravascular volume depletion, supporting the pharmacokinetic robustness of long-acting antiretroviral therapy in major surgical settings. - A Case of Acute Myeloid Leukemia with MOZ::TIF2 Fusion Gene Resulting from a Novel Breakpoint.
Toma Suzuki; Masahiro Onozawa; Minoru Kanaya; Takeshi Kondo; Shunsuke Sugimura; Jun Nagai; Keito Yokoyama; Yumika Saito; Shota Yoshida; Shinpei Harada; Keito Suto; Yuta Hasegawa; Takahide Ara; Hideki Goto; Daigo Hashimoto; Takanori Teshima
Internal medicine (Tokyo, Japan), 21 Apr. 2026, [Domestic magazines]
English, Scientific journal, We report a rare case of acute myeloid leukemia (AML) harboring an MOZ::TIF2 fusion gene with a previously unreported breakpoint. A 36-year-old man was diagnosed with AML involving inv(8)(p11.2q13). Reverse transcriptase-polymerase chain reaction (RT-PCR) initially failed to detect the conventional MOZ exon16::TIF2 exon14 fusion associated with inv(8)(p11.2q13); however, further sequencing identified a novel breakpoint of MOZ exon14::TIF2 exon12, with an additional shorter transcript lacking TIF2 exon13. MOZ::TIF2-positive AML is extremely rare, with only eight cases previously reported, and adult cases appear to have particularly poor outcomes. Our case highlights the diagnostic challenges and aggressive clinical behavior associated with MOZ::TIF2-rearranged AML. - HLA-matched versus haploidentical donor transplantation with post-transplant cyclophosphamide: a study on behalf of the donor/source working group of the Japanese society for transplantation and cellular therapy.
Yosuke Nakaya; Hirohisa Nakamae; Junichi Sugita; Junya Kanda; Yuta Hasegawa; Tetsuya Eto; Takahiro Fukuda; Naoki Kurita; Nobuhiro Hiramoto; Koji Nagafuji; Shuichi Ota; Noboru Asada; Toshihiko Ando; Toshiro Kawakita; Takashi Akasaka; Yasuo Mori; Tomohiko Kamimura; Makoto Onizuka; Yoshiko Atsuta; Hideki Nakasone
Annals of hematology, 105, 5, 20 Apr. 2026, [International Magazine]
English, Scientific journal, UNLABELLED: Post-transplant cyclophosphamide (PTCy) is now being increasingly applied to HLA-matched donor (MD) transplantation. Prior studies in Western countries have demonstrated that allogeneic hematopoietic cell transplantation (allo-HCT) employing PTCy yields better outcomes with HLA-matched donors (MDs) than with haploidentical donors (HIDs). However, the effect of HLA mismatch may differ among racial groups. We retrospectively analyzed adult patients with hematological malignancies who underwent their first allo-HCT with PTCy from MDs or HIDs registered to the Japanese registry database between 2013 and 2021. Among 63 (related, n = 33; unrelated, n = 30) and 1261 patients who received MD and HID allo-HCT with PTCy, 50 (related, n = 30; unrelated, n = 20) and 100 patients were assigned to MD and HID groups by 1:2 propensity score matching (PSM). The results showed that MD recipients had better neutrophil recovery (hazard ratio [HR], 1.48; 95% confidence interval [CI], 1.04–2.10; P = 0.031) and lower risk of non-relapse mortality (NRM) (HR, 0.19; 95% CI, 0.05–0.81; P = 0.024) than HID recipients. Multivariable analyses in the entire cohort before PSM confirmed these findings. Fatal infection was the primary cause of NRM in the HID group. This study is the first to demonstrate that, within a homogeneous Asian cohort, MD may have an advantage over HID in PTCy-based allo-HCT in facilitating neutrophil engraftment and reducing the risk of NRM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00277-026-07014-z. - Donor selection for patients with HLA-homozygous haplotypes in allogeneic hematopoietic stem cell transplantation.
Noriyoshi Yoshinaga; Makoto Iwasaki; Koji Kato; Fumihiko Kimura; Masahiro Hirayama; Minoru Kanaya; Satoko Morishima; Naoyuki Uchida; Noriko Doki; Takahiro Fukuda; Yoshinobu Kanda; Tetsuya Nishida; Yuta Hasegawa; Shinichi Kako; Masatsugu Tanaka; Mineo Kurokawa; Noboru Asada; Toshiro Kawakita; Keisuke Kataoka; Yukio Kondo; Kazunori Imada; Tatsuo Ichinohe; Makoto Onizuka; Yoshiko Atsuta; Junya Kanda
Annals of hematology, 105, 5, 14 Apr. 2026, [International Magazine]
English, Registry analysis of first allogeneic transplant in HLA-homozygous recipients.Overall survival did not significantly differ with related donor hetero-to-homo or cord blood hetero-to-homo transplantation.Cord blood homo-to-homo transplantation was associated with inferior survival in the primary analysis. - Significant clinical impact of immunosuppressive therapy termination after allogeneic haematopoietic stem cell transplantation
Shigeo Fuji; Akihiro Ohmoto; Yuho Najima; Kazuki Yoshimura; Naoyuki Uchida; Masatsugu Tanaka; Yuta Hasegawa; Takahiro Fukuda; Noboru Asada; Masashi Sawa; Mamiko Sakata‐Yanagimoto; Masataka Ishimura; Makoto Onizuka; Tetsuya Nishida; Noriko Doki; Koji Kawamura; Moeko Hino; Yoshinobu Kanda; Yoshiko Atsuta; Kimikazu Yakushijin
British Journal of Haematology, Wiley, 22 Mar. 2026
Scientific journal, Summary
The clinical impact of immunosuppression termination (IST) after allogeneic haematopoietic stem cell transplantation (allo‐HSCT) remains to be fully elucidated. This study was aimed at assessing the impact of IST within 2 years after transplantation on subsequent clinical outcomes. We analysed data for patients from the Transplant Registry Unified Management Program 2 (TRUMP 2) database who survived without progression for at least 2 years after allo‐HSCT. Of the 5061 patients whose median age was 48 (range: 0–79) years, 2320 discontinued immunosuppressive therapy within 2 years (IST group), while 2741 did not (non‐IST group). The 4‐year overall survival (OS) rate was significantly higher in the IST group than in the non‐IST group (95.3% vs. 90.8%; p < 0.01). The 4‐year cumulative incidence of non‐relapse mortality (NRM) was significantly lower in the IST group than in the non‐IST group (3.5% vs. 8.6%; p < 0.01). This reduction in NRM was consistent across major causes, including graft‐versus‐host disease (GVHD)‐related mortality, infection‐related mortality and organ failure‐related mortality. Immunosuppressive therapy beyond 2 years after allo‐HSCT was associated with inferior OS. Our findings suggest that the optimal transplant strategy is necessary to avoid long‐term immunosuppression for improving clinical outcomes in allo‐HSCT recipients. - Platelet Recovery and Its Impact on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation: A Japanese Nationwide Retrospective Study.
Naoki Kurita; Kazushi Maruo; Fumihiko Kimura; Yachiyo Kuwatsuka; Toshihiro Matsukawa; Takaaki Konuma; Shinichi Kobayashi; Mamiko Sakata-Yanagimoto; Noriko Doki; Masatsugu Tanaka; Naoyuki Uchida; Tetsuya Nishida; Masashi Sawa; Yuta Hasegawa; Hirohisa Nakamae; Shuichi Ota; Makoto Onizuka; Takahiro Fukuda; Nobuhiro Hiramoto; Toshiro Kawakita; Noboru Asada; Fumihiko Ishimaru; Junya Kanda; Ken Tabuchi; Yoshiko Atsuta; Hideki Nakasone
American journal of hematology, 101, 1, 193, 197, Jan. 2026, [International Magazine]
English, Scientific journal, In this Japanese registry-based analysis of 9105 adult patients with acute leukemia undergoing allogeneic hematopoietic stem cell transplantation, a marked difference in survival was observed based on platelet levels: ≤ 20 × 109/L, 20-50 × 109/L, and > 50 × 109/L. The number of patients with thrombocytopenia receiving cord blood (CB, 39%) was significantly larger than those receiving unrelated bone marrow (uBM, 17%) on Day 50 (p < 0.001); however, this difference disappeared on Day 100 posttransplantation (both 11%, p = 0.4). - Letermovir prophylaxis and risk of bacterial or fungal infection after allogeneic hematopoietic cell transplantation.
Shun-Ichi Kimura; Shunto Kawamura; Takashi Toya; Keiji Okinaka; Hiroki Hosoi; Naoyuki Uchida; Noriko Doki; Tetsuya Nishida; Masatsugu Tanaka; Yuta Hasegawa; Yoshinobu Kanda; Noboru Asada; Naoki Kurita; Hirohisa Nakamae; Tetsuya Eto; Makoto Yoshimitsu; Makoto Onizuka; Takahiro Fukuda; Marie Ohbiki; Yoshiko Atsuta; Kimikazu Yakushijin
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 32, 1, 102888, 102888, 08 Dec. 2025, [International Magazine]
English, Scientific journal, BACKGROUND: Previous reports have suggested an association between cytomegalovirus (CMV) infection and bacterial or fungal infections after allogeneic hematopoietic cell transplantation (HCT). This study aimed to examine the relationship between letermovir (LTV) prophylaxis and the incidence of bacteremia and invasive fungal infections. METHODS: Using a Japanese transplant registry database, we analyzed 19,531 patients who underwent their first allogeneic HCT from 2011 to 2022. Patients who initiated LTV prophylaxis within the first week post-transplantation were classified as the LTV group. RESULTS: A total of 4915 patients in the LTV group and 14,616 in the No LTV group were analyzed. The incidence of bacteremia by day 100 was significantly lower in the LTV group compared to the No LTV group (17.4 % vs. 21.7 %, P < 0.001). In the multivariate analysis, LTV prophylaxis (HR 0.75, 95 %CI: 0.69-0.81) was found to be significantly associated with a reduced risk of bacteremia, along with neutrophil engraftment. Age >50 years, male, non-remission status, alternative donors, higher values of the hematopoietic cell transplantation-comorbidity index, poor performance status, and grade II-IV acute graft-versus-host disease were associated with an increased risk of bacteremia. LTV was associated with a reduced risk of bacteremia both within 30 days (HR 0.74, 95 %CI: 0.68-0.81) and beyond 30 days (HR 0.76, 95 %CI: 0.66-0.89) after HCT. Conversely, it was not associated with the risk of invasive aspergillosis or candidemia. CONCLUSIONS: LTV prophylaxis significantly reduced the risk of bacteremia. However, it was not associated with the risk of invasive fungal infections. - Risk Stratification Using Dynamic International Prognostic Scoring System and Splenomegaly in Myelofibrosis Treated with Pretransplant JAK Inhibitors.
Yosuke Okada; Kazuki Sakatoku; Shuichi Shirane; Makoto Murata; Katsuto Takenaka; Yasuharu Hamano; Noriko Doki; Yoshinobu Kanda; Naoyuki Uchida; Masatsugu Tanaka; Tetsuya Nishida; Jun Ishikawa; Noboru Asada; Yuta Hasegawa; Shinichiro Machida; Yasuo Mori; Tetsuya Eto; Makoto Yoshimitsu; Takahiro Fukuda; Yoshiko Atsuta; Takayoshi Tachibana
Transplantation and cellular therapy, 31, 12, 1008.e1-1008.e11, Dec. 2025, [International Magazine]
English, Scientific journal, The Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis (MF) has been reported to predict transplant outcomes in MF patients. Recently, the pretransplant use of JAK inhibitors has become common in clinical practice, but it is unclear whether DIPSS is also useful for predicting transplant outcomes for these patients. In this study, we compared the prognostic impact of DIPSS between MF patients with and without pretransplant ruxolitinib therapy. DIPSS stratified overall survival (OS) in patients without pretransplant ruxolitinib therapy (P = .002), but not in those with it (P = .23). In an exploratory analysis, palpable splenomegaly appeared to be a potential prognostic factor among patients who received pretransplant ruxolitinib therapy (hazard ratio [HR] 1.53, 95% confidence interval [CI]: 0.86 to 2.72, P = .15). Here we propose a modified scoring system, DIPSS with Splenomegaly (DIP3S), and demonstrate that DIP3S high-risk status (defined as DIPSS low-, intermediate-1-, and intermediate-2-risk with splenomegaly, or DIPSS high-risk) is independently associated with inferior OS (HR 2.20, 95% CI: 1.09 to 4.45, P = .027), delayed neutrophil engraftment (HR 0.54, 95% CI: 0.37 to 0.77, P < .001), and delayed platelet engraftment (HR 0.32, 95% CI: 0.20 to 0.52, P < .001). On the other hand, neither DIPSS (HR 0.62, 95% CI: 0.34 to 1.12, P = .11 for low/intermediate-1-risk; HR 0.96, 95% CI: 0.50 to 1.84, P = .90 for high-risk) nor splenomegaly (HR 1.51, 95% CI: 0.83 to 2.75, P = .17) was significantly associated with inferior OS when each factor was independently included in the multivariable analysis. Therefore, the DIP3S risk may be able to identify high-risk patients among those who receive pretransplant JAK inhibitors. Further validation studies are needed to clarify the prognostic impact of DIP3S. - Risk Factors for and Impact of Pre-Engraftment Syndrome on Outcomes Following Single-Unit Cord Blood Transplantation in Adults.
Masatoshi Sakurai; Keisuke Kataoka; Kota Mizuno; Takuto Mori; Shuichi Shirane; Hirotoshi Sakaguchi; Takehiko Mori; Masatsugu Tanaka; Masahito Tokunaga; Makoto Onizuka; Mamiko Sakata-Yanagimoto; Jun Ishikawa; Yuta Katayama; Shuichi Ota; Masashi Sawa; Jun Kato; Yuta Hasegawa; Koichi Onodera; Norimichi Hattori; Shigesaburo Miyakoshi; Nobuyuki Takayama; Tetsuya Nishida; Koji Kato; Fumihiko Ishimaru; Yoshiko Atsuta; Junya Kanda; Hideki Nakasone; Seitaro Terakura
American journal of hematology, 100, 12, 2248, 2260, Dec. 2025, [International Magazine]
English, Scientific journal, Pre-engraftment syndrome (PES) is a unique complication of cord blood transplantation (CBT) whose risk factors and impact on transplant outcomes remain controversial. Using a nationwide database in Japan, we analyzed a total of 3734 patients who underwent single-unit CBT. PES occurred in 18.3% of patients, and risk factors for PES included a higher hematopoietic cell transplantation-specific comorbidity index, first transplantation, myeloablative conditioning (MAC), lower total nucleated cell (TNC) dose, and graft-versus-host disease (GVHD) prophylaxis regimens excluding tacrolimus with methotrexate. Patients who developed PES had significantly higher incidences of grade II-IV acute GVHD (53.1% vs. 31.3%, p < 0.001) and chronic GVHD (27.2% vs. 21.7%, p = 0.002) compared to those without PES. Landmark analysis with multivariable adjustment revealed that PES was independently associated with increased non-relapse mortality (NRM, hazard ratio [HR] 1.46; 95% CI 1.22-1.75; p < 0.001), reduced relapse incidence (HR 0.78; 95% CI 0.63-0.96; p = 0.020), and a trend toward inferior overall survival (OS, HR 1.13; 95% CI 0.98-1.30; p = 0.088). Moreover, patients who experienced both PES and acute GVHD had the highest 2-year NRM (31.7%; 95% CI 26.0%-37.6%) and the lowest 2-year OS (55.9%; 95% CI 50.0%-62.4%), compared with those who experienced either PES (NRM 20.7%; OS 65.0%) or acute GVHD (NRM 19.5%; OS 62.8%) (p < 0.001), highlighting the combined effects of these complications. This study, the largest to date on PES, demonstrates its clinical significance as an early complication with lasting effects on transplant outcomes. - Safety and Efficacy of Graft-versus-Host Disease Prophylaxis with Mini-Dose Methotrexate in Umbilical Cord Blood Transplantation: An NJHSG-CBT18 Observational Study.
Souichi Shiratori; Keito Suto; Yuta Hasegawa; Takahide Ara; Toshihiro Matsukawa; Hideki Goto; Masahiro Onozawa; Masao Nakagawa; Kaoru Kahata; Daisuke Hidaka; Reiki Ogasawara; Kohei Okada; Junichi Sugita; Yasutaka Kakinoki; Shuichi Ota; Daigo Hashimoto; Takanori Teshima
Transplantation and cellular therapy, 06 Nov. 2025, [International Magazine]
English, Scientific journal, Tacrolimus (Tac) and methotrexate (MTX) are standard graft-versus-host disease (GVHD) prophylaxis for umbilical cord blood transplantation (CBT); however, the optimal dose of MTX for CBT remains to be determined. We previously showed the safety and efficacy of reduced-dose MTX (mini-MTX; 5 mg/m2 on days 1, 3, and 6) combined with Tac as GVHD prophylaxis for CBT in a single-center retrospective study. Here we report a multicenter observational study in the North Japan Hematology Study Group (NJHSG; NJHSG-CBT18) conducted to evaluate transplantation outcomes according to GVHD prophylaxis in single-unit CBT, in which patients with hematologic malignancies scheduled for CBT were prospectively registered and followed for 2 years after CBT. A total of 112 patients were registered in NJHSG-CBT18, with a median age of 51 years. Eighty-nine patients received Tac + mini-MTX, 19 patients received Tac + mycophenolate mofetil (MMF), and 4 patients received Tac only as GVHD prophylaxis. Multivariate analysis identified GVHD prophylaxis other than Tac + mini-MTX as a significant risk factor for nonrelapse mortality (NRM) (hazard ratio [HR], 0.160; 95% confidence interval [CI], 0.065 to 0.391; P < .001), overall survival (OS) (HR, 2.971; 95% CI, 1.558 to 5.663; P < .001), progression-free survival (PFS) (HR, 2.383; 95% CI, 1.345 to 4.222; P = .003), and GVHD-free, relapse-free survival (GRFS) (HR, 3.075; 95% CI, 1.799 to 5.256; P < .001). In a comparison of clinical outcomes between the mini-MTX and MMF groups, the cumulative incidences of pre-engraftment immune reaction (5.7% versus 42.1%; P < .001), human herpesvirus 6 encephalitis (2.3% versus 15.8%, P = .011), grade II-IV acute GVHD (14.6% versus 47.4%, P < .001), and NRM (1.1% versus 52.6%, P < .001) were significantly lower and the cumulative incidence of immunosuppressant discontinuation was significantly higher (66.3% versus 18.4%, P = .004) in the mini-MTX group compared to the MMF group, while rates of chronic GVHD and relapse were comparable between the groups. The probabilities of OS (70.6% versus 31.6%, P < .001), PFS (58.1 versus 14.0%, P < .001), and GRFS (44.9% versus 5.1%, P < .001) were significantly higher in the mini-MTX group. Multivariate analysis of risk factors for OS in the mini-MTX group identified high-risk or very high-risk refined Disease Risk Index (rDRI) (HR, 3.896; 95% CI, 1.575 to 9.637; P = .003) and high HCT-CI (HR, 3.338; 95% CI, 1.301 to 8.569; P = .012) as significant risk factors for OS. Our data indicate that a combination of Tac + mini-MTX is safe and effective GVHD prophylaxis in CBT. - Analyses of transplantation outcomes for adult patients with mixed-phenotype acute leukemia.
Tomoyasu Jo; Tadakazu Kondo; Shohei Mizuno; Shinichi Kako; Noriko Doki; Naoyuki Uchida; Masatsugu Tanaka; Tetsuya Nishida; Takahiro Fukuda; Masashi Sawa; Yoshinobu Kanda; Satoru Takada; Yuta Hasegawa; Yuta Katayama; Satoshi Yoshihara; Koji Kawamura; Marie Ohbiki; Yoshiko Atsuta; Masamitsu Yanada; Yasuyuki Arai
Blood neoplasia, 2, 4, 100166, 100166, Nov. 2025, [International Magazine]
English, Scientific journal, Mixed-phenotype acute leukemia (MPAL) is associated with poor prognosis. Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) can achieve long-term survival, optimal transplantation strategies remain unclear. We analyzed a national registry of adult patients with MPAL who underwent allo-HSCT between 2008 and 2022 in Japan. Among 417 patients, median age at transplant was 44 years (interquartile range, 32-55); 61% were male, 20% were BCR::ABL1-positive, and 66% underwent transplant during the first complete remission (CR; CR1). At 5 years posttransplant, overall survival (OS) was 54%, disease-free survival was 49%, relapse was 28%, and nonrelapse mortality was 23%. Multivariate analysis identified older age (adjusted hazard ratio [aHR], 1.78 [95% confidence interval (CI), 1.11-2.84] for ages 50-59 years; aHR, 2.65 [95% CI, 1.54-4.55] for ≥60 years; both vs <40 years), male sex (aHR, 1.56; 95% CI, 1.07-2.27), Eastern Cooperative Oncology Group performance status scale ≥2 (aHR, 3.05; 95% CI, 1.72-5.40), BCR::ABL1 -negative status (aHR, 1.64; 95% CI, 1.02-2.64), advanced disease status (aHR, 1.642 [95% CI, 0.80-3.36] for second CR; aHR, 4.01 [95% CI, 2.61-6.15] for third or higher CR, or non-CR vs CR1), and low conditioning intensity (aHR, 2.49 [95% CI, 1.21-5.13] for low transplant conditioning intensity [TCI] vs high TCI) as adverse prognostic factors for OS. A propensity score-matched comparison with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) during the same period showed that MPAL did not have significantly worse prognosis than AML or ALL. These findings suggest that allo-HSCT offers long-term survival in MPAL, with outcomes not inferior to those of AML and ALL. - Impact of methotrexate-dosing regimens for GVHD prophylaxis on clinical outcomes of HLA-matched allogeneic HSCT.
Tomotaka Suzuki; Tomoyasu Jo; Kota Yoshifuji; Tadakazu Kondo; Noriko Doki; Yoshinobu Kanda; Tetsuya Nishida; Yasushi Onishi; Noboru Asada; Takahiro Fukuda; Masashi Sawa; Yuta Hasegawa; Kentaro Serizawa; Shuichi Ota; Masatsugu Tanaka; Makoto Yoshimitsu; Yoshiko Atsuta; Junya Kanda
British journal of haematology, 19 Oct. 2025, [International Magazine]
English, Scientific journal, Severe graft-versus-host disease (GVHD) remains a major complication of allogeneic haematopoietic stem cell transplantation (allo-HSCT), necessitating optimal immunosuppressive strategies. This retrospective study used data from the Japanese Transplant Registry Unified Management Program to compare three methotrexate (MTX)-dosing regimens for GVHD prophylaxis in patients undergoing human leucocyte antigen (HLA)-matched allo-HSCT: a low-dose 3-day regimen (Ld3:10 mg/m2 on day 1, 7 mg/m2 on days 3 and 6), a low-dose 4-day regimen (Ld4: Ld3 with an additional 7 mg/m2 on day 11) and an original-dose 3-day regimen (Od3: 15 mg/m2 on day 1, 10 mg/m2 on days 3 and 6). Among 2537 analysed patients, Ld3 was the most commonly used regimen. Multivariate analyses showed no significant differences in the cumulative incidence of grade II-IV acute GVHD among regimens. However, Od3 was associated with an increased risk of grade III-IV acute GVHD, and Ld4 was linked to delayed neutrophil engraftment. This study is the first large-scale retrospective analysis of the impact of different MTX-dosing regimens on the outcomes of HLA-matched allo-HSCT, providing valuable insights into optimal MTX-dosing strategies in clinical practice. - Comparison of single-unit umbilical cord blood transplantation and haploidentical transplantation using posttransplant cyclophosphamide during first complete remission of acute myeloid leukemia.
Masamitsu Yanada; Satoshi Yamasaki; Shohei Mizuno; Junichi Sugita; Takahiro Fujino; Yukiko Misaki; Masatsugu Tanaka; Naoyuki Uchida; Makoto Onizuka; Noriko Doki; Shuichi Ota; Masashi Sawa; Toshiro Kawakita; Yuta Hasegawa; Hirohisa Nakamae; Kazuya Ishiwata; Nobuhiro Hiramoto; Fumihiko Ishimaru; Junya Kanda; Marie Ohbiki; Yoshiko Atsuta; Hideki Nakasone; Takaaki Konuma
Bone marrow transplantation, 05 Oct. 2025, [International Magazine]
English, Scientific journal, Choosing an optimal alternative donor is an important clinical concern in allogeneic hematopoietic cell transplantation (HCT). In Japan, single-unit umbilical cord blood transplantation (UCBT) has been widely used in the last two decades, whereas HCT from HLA-haploidentical related donors (haplo-HCT) has been increasingly used following the advent of posttransplant cyclophosphamide (PTCY) for graft-versus-host disease (GVHD) prophylaxis. This registry-based study aimed to compare outcomes between single-unit UCBT (n = 848) and PTCY-based haplo-HCT (n = 241) performed during first complete remission in patients with acute myeloid leukemia. UCBT was associated with a lower likelihood of engraftment (P < 0.001), a higher risk of grade 2-4 and grade 3-4 acute GVHD (P = 0.003 each), and a lower risk of extensive chronic GVHD (P = 0.048). The UCBT and haplo-HCT groups did not significantly differ in 3-year probabilities of overall survival (68% versus 69%, P = 0.686), GVHD/relapse-free survival (55% versus 54%, P = 0.866), relapse (14% versus 16%, P = 0.463), and non-relapse mortality (21% versus 19%, P = 0.403), respectively, which were confirmed with multivariate analysis. These results indicate that both procedures should be considered viable options for patients lacking a matched donor. - 臍帯血移植におけるGVHD予防法が移植後CMV感染に与える影響
川村 俊人; 赤星 佑; 仲宗根 秀樹; 内田 直之; 鬼塚 真仁; 片岡 圭亮; 加藤 剛二; 坂田 麻実子[柳元]; 澤 正史; 田中 正嗣; 東梅 友美; 土岐 典子; 西田 徹也; 長谷川 祐太; 前田 猛; 松井 俊大; 村主 啓行; 和氣 敦; 大引 真理恵; 神田 善伸; 熱田 由子; 諫田 淳也; 藥師神 公和
日本血液学会学術集会, 87回, O3, 1, (一社)日本血液学会, Oct. 2025
English - 急性骨髄性白血病におけるFLT3-ITD/NPM1変異と同種移植成績との関連
柳田 正光; 山崎 聡; 細井 裕樹; 水野 昌平; 原田 介斗; 土岐 典子; 藤原 慎一郎; 平本 展大; 長谷川 祐太; 石綿 一哉; 西田 徹也; 淺田 騰; 鈴木 琢磨; 坂田 麻実子[柳元]; 内田 直之; 諫田 淳也; 吉満 誠; 神田 善伸; 福田 隆浩; 大引 真理恵; 熱田 由子; 小沼 貴晶
日本血液学会学術集会, 87回, O2, 4, (一社)日本血液学会, Oct. 2025
English - The Impact of Tirabrutinib Monotherapy for the Treatment of Bing-Neel Syndrome: A Multicenter Retrospective Study.
Masuho Saburi; Taro Masunari; Noriko Fukuhara; Yuichiro Inagaki; Arika Shimura; Naoto Imoto; Yuta Hasegawa; Masao Hagihara; Nobuhiko Kobayashi; Hanae Kumekawa; Hideyuki Nakazawa; Kana Miyazaki; Toshiro Kawakita; Takahiro Isshiki; Atsushi Katsube; Shin Fujisawa; Yuichi Horigome; Yusuke Koba; Fumiaki Jinnouchi; Naohiro Sekiguchi
American journal of hematology, 100, 10, 1912, 1915, 02 Aug. 2025, [International Magazine]
English - A win ratio approach for comparing graft-versus-host disease-free, relapse-free survival among alternative donors.
Yoshimitsu Shimomura; Sho Komukai; Tetsuhisa Kitamura; Kazuki Yoshimura; Yoshihiro Inamoto; Yu Akahoshi; Yachiyo Kuwatsuka; Yoshiaki Usui; Naoyuki Uchida; Masatsugu Tanaka; Makoto Onizuka; Mamiko Sakata-Yanagimoto; Noriko Doki; Yuta Hasegawa; Kazuya Ishiwata; Hirohisa Nakamae; Masashi Sawa; Yuta Katayama; Toshiro Kawakita; Makoto Yoshimitsu; Takahiro Fukuda; Yoshinobu Kanda; Marie Ohbiki; Hideki Nakasone; Junya Kanda
British journal of haematology, 207, 3, 946, 955, 16 Jul. 2025, [International Magazine]
English, Scientific journal, The optimal alternative donor type for patients lacking human leucocyte antigen (HLA)-matched related or unrelated donors remains unclear. In comparative studies evaluating donor types, graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS) represents a well-established end-point but has limitations. The win ratio approach addresses these limitations by analysing multiple end-points with varying severities to account for the relative component priorities. We compared HLA-mismatched unrelated donors, haploidentical donors and cord blood using both the hazard ratio (HR) of GRFS and the win ratio related to GRFS. The haploidentical donor group had a similar HR of GRFS (HR: 1.01, 95% confidence interval [CI]: 0.85-1.19, p = 0.916) and win ratio (win ratio: 0.86, 95% CI: 0.72-1.02, p = 0.081) to HLA-mismatched unrelated donors. Cord blood transplantation showed similar GRFS compared to HLA-mismatched unrelated donors in the Cox proportional model (HR: 1.14, 95% CI: 0.98-1.32, p = 0.085), significantly lower win ratio (win ratio: 0.80, 95% CI: 0.68-0.93, p = 0.004) and similar outcomes to haploidentical donors. HLA-mismatched unrelated donor transplantation showed comparable to superior outcomes among alternative donor types. Our results indicate the need to present the win ratio alongside conventional methods to assess the end-point robustly. - Impact of Conditioning Intensity on Clinical Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Relapse After First Transplantation.
Kazuki Yoshimura; Hideki Nakasone; Masaharu Tamaki; Hiroki Hosoi; Kazuaki Kameda; Naoyuki Uchida; Noriko Doki; Takahiro Fukuda; Satoshi Yoshihara; Yasuo Mori; Hirohisa Nakamae; Masatsugu Tanaka; Yuta Katayama; Tetsuya Eto; Yuta Hasegawa; Shuichi Ota; Satoshi Takahashi; Makoto Yoshimitsu; Fumihiko Ishimaru; Junya Kanda; Yoshiko Atsuta; Kimikazu Yakushijin
American journal of hematology, 100, 7, 1185, 1195, 23 May 2025, [International Magazine]
English, Scientific journal, Although second allogeneic hematopoietic cell transplantation HCT (HCT2) is a potentially curative treatment for patients relapsing after their first HCT (HCT1), it is associated with higher non-relapse mortality (NRM) compared with HCT1. Furthermore, while reduced-intensity conditioning (RIC) in HCT2 might decrease NRM, there is no consensus on which patients may benefit from RIC. We retrospectively analyzed 2478 patients who underwent HCT2 for relapse of hematologic malignancies after HCT1. In a multivariate analysis, older recipient age, short duration between HCT1 and HCT2, RIC in HCT1, HCT-CI ≥ 2, and ECOG PS ≥ 2 were associated with an increased risk of NRM. RIC in HCT2 was associated with better NRM compared to myeloablative conditioning (MAC) (hazard ratio [HR] 0.83, 95% confidence interval [CI]: 0.72-0.97; p = 0.018), but was not significantly associated with overall survival (OS) (HR 0.91, 95% CI: 0.82-1.01; p = 0.075). We observed a significant interaction for NRM between extensive cGVHD in HCT1 and the conditioning intensity of HCT2 (interaction p < 0.001), meaning that the benefit of RIC in HCT2 was seen in patients with extensive cGVHD in HCT1, but not in those without cGVHD. RIC in HCT2 was also associated with superior OS in patients with extensive cGVHD in HCT1 (HR 0.68, 95% CI: 0.49-0.93; p = 0.02), with significant interaction between the conditioning intensity and the prior history of extensive cGVHD (interaction p = 0.01). This study suggests that RIC in HCT2 reduces NRM for HCT2 and improves OS, especially in patients with a history of extensive cGVHD. - Safety of hematopoietic stem cell donation from young related donors following the lowering of the age of legal adulthood in Japan.
Tsuneaki Hirakawa; Hiromasa Yabe; Masayuki Hino; Noriko Doki; Satoshi Yoshihara; Shuichi Ota; Takahiro Fukuda; Hirohisa Nakamae; Jun Ishikawa; Yuta Hasegawa; Tetsuya Nishida; Noboru Asada; Hidekazu Nishikii; Toshiro Kawakita; Masayoshi Masuko; Yasuo Mori; Toshihiko Ando; Kazuhiko Ikeda; Marie Ohbiki; Yoshiko Atsuta; Nobuhiro Tsukada; Ryu Yanagisawa
International journal of hematology, 122, 4, 572, 582, 20 May 2025, [Domestic magazines]
English, Scientific journal, The Japanese government's recent lowering of the legal adult age to 18 may prompt reconsideration of the minimum age for donors in the Japan Marrow Donor Program. To provide foundational data for decision-makers, this retrospective study analyzed the safety of hematopoietic stem cell donation among 1999 related donors aged 18 to 24 years, using data from the Japanese Data Center for Hematopoietic Cell Transplantation. Severe adverse events (SAEs) occurred in 1.0% of all donors, with no significant difference between those aged 18 to 19 (0.7%) and those aged 20 to 24 (1.1%) (P = 0.59). Risk factors for SAEs included ongoing asthma treatment (HR 34.6, 95% CI 2.29-524.00, P < 0.01), history of asthma (HR 11.3, 95% CI 2.46-51.70, P < 0.01), and female sex (HR 4.64, 95% CI 1.51-14.20, P < 0.01). However, age of 18 to 19 was not a significant risk factor (HR 0.53, 95% CI 0.14-2.01, P = 0.35). These results indicate that stem cell donation safety in 18- to 19-year-old donors is comparable to that in 20- to 24-year-olds, with increased risks linked to asthma and female sex. - Optimal Depth of the Treatment Response Before Allogeneic Hematopoietic Transplantation for Chronic Myeloid Leukemia in Chronic Phase.
Yosuke Okada; Takeshi Kondo; Takuya Miyazaki; Yutaka Shimazu; Yosuke Minami; Fumihiko Ouchi; Shinichi Kako; Masatsugu Tanaka; Tetsuya Nishida; Shin-Ichiro Fujiwara; Naoyuki Uchida; Hirohisa Nakamae; Yuta Hasegawa; Keisuke Kataoka; Shingo Yano; Mamiko Sakata-Yanagimoto; Ayumu Ito; Jun Ishikawa; Yoshinobu Kanda; Koji Kawamura; Takahiro Fukuda; Yoshiko Atsuta; Takayoshi Tachibana
American journal of hematology, 100, 8, 1440, 1443, 12 May 2025, [International Magazine]
English - Adverse Impact of Pre-Transplant Liver Dysfunction in Allogeneic Hematopoietic Cell Transplantation.
Yukiko Misaki; Masaharu Tamaki; Ryu Yanagisawa; Noriko Doki; Naoyuki Uchida; Masatsugu Tanaka; Tetsuya Nishida; Masashi Sawa; Yuta Hasegawa; Shuichi Ota; Makoto Onizuka; Sakata-Yanagimoto Mamiko; Yuta Katayama; Noboru Asada; Junya Kanda; Takahiro Fukuda; Yoshiko Atsuta; Yoshinobu Kanda; Kimikazu Yakushijin; Hideki Nakasone
American journal of hematology, 100, 5, 821, 829, May 2025, [International Magazine]
English, Scientific journal, Although the hematopoietic cell transplantation (HCT)-comorbidity index (HCT-CI) score is associated with an increased risk of mortality after allogeneic HCT, it remains unclear how pre-HCT liver dysfunction affects clinical outcomes. We retrospectively compared clinical HCT outcomes among four groups stratified according to the presence of HCT-CI liver and other organ scores, using a Japan transplant registry database between 2010 and 2020. Of the 14235 recipients, 1527 tested positive for an HCT-CI liver score including HBV or HCV hepatitis (n = 503). The 5-year overall survival (OS) was significantly lower in the HCT-CI liver(+) other(+) and HCT-CI liver(-) other(+) groups compared to the HCT-CI liver(+) other(-) and HCT-CI liver(-) other(-) groups [49.9% vs. 59% vs. 66.5% vs. 68.3%, p < 0.001]. A multivariate analysis showed that both the HCT-CI liver(+) other(+) [HR 1.62, p < 0.001] and HCT-CI liver(-) other(+) groups [HR 1.21, p < 0.001] were significantly associated with inferior OS. Similarly, both the HCT-CI liver(+) other(+) [HR 1.89, p < 0.001] and liver(-) other(+) groups [HR 1.26, p < 0.001] were significantly associated with an increased risk of NRM. On the other hand, the HCT-CI liver(+) other(-) group was not associated with either OS or NRM. Separately analyzing the subcohorts with or without HCT-CI other scores, the presence of an HCT-CI liver score alone did not affect survival, while the co-presence of pretransplant liver dysfunction seemed to synergistically increase the adverse impact on OS and NRM among recipients with other organ comorbidities. Further studies will be needed to identify optimal strategies for recipients with pretransplant liver dysfunction. - Heterogeneity of Survival Benefit Conferred By Letermovir.
Yu Akahoshi; Hideki Nakasone; Katsuto Takenaka; Takahide Ara; Yuma Tada; Noriko Doki; Naoyuki Uchida; Masatsugu Tanaka; Yuta Hasegawa; Wataru Takeda; Tetsuya Nishida; Jun Ishikawa; Naoki Kurita; Masashi Sawa; Makoto Onizuka; Shinichi Kako; Shin-Ichiro Fujiwara; Keisuke Kataoka; Koji Kawamura; Takahiro Fukuda; Yoshiko Atsuta; Kimikazu Yakushijin; Yoshinobu Kanda
Transplantation and cellular therapy, 31, 7, 461.e1-461.e12, 28 Apr. 2025, [International Magazine]
English, Scientific journal, Variation in treatment effects based on individual patient characteristics-known as treatment effect heterogeneity or effect modification-has recently gained significant attention. A previous clinical trial and its post hoc analysis suggested that letermovir (LTV) may reduce mortality more in some patients than in others. We hypothesized that the survival benefit of LTV differs according to each patient's specific characteristics. This study aimed to identify patient characteristics that are associated with significant survival benefits from LTV. Patients who underwent transplantation between 2018 and 2022 were randomly divided into training (n = 5779) and validation groups (n = 2865). We developed two models: one using a proportional hazards model with interaction terms (PI), and another using a modern machine learning (ML) approach to detect heterogeneity in the survival benefit-specifically, to identify patient characteristics associated with greater benefit from LTV. In our cohort, 60% of patients received LTV as prophylaxis. In the training cohort, the final PI model, using additive interactions, identified advanced age (≥60), high comorbidities (HCT-CI ≥3), umbilical cord blood (UCB), and haploidentical HCT with post cyclophosphamide (PTCy Haplo) as highly beneficial factors. Meanwhile, the ML model, using a causal forest algorithm, classified the top 60% of patients based on the estimated individual treatment effect as the high benefit group. In the validation group, 67.1% and 59.9% of patients were considered to be high benefit by the PI and ML models, respectively. The absolute difference in 6-month NRM (LTV versus no LTV) in the high benefit group (PI model: 9.8% versus 16.3%; ML model: 11.3% versus 16.3%) was greater than that in the low benefit group (PI model: 4.3% versus 6.9%; ML model: 4.1% versus 6.2%). Most patients (>80%) with advanced age, high comorbidities, or UCB were classified as high benefit by the ML model, supporting the robustness of the PI model. Our models successfully identified patients who could be expected to experience lower NRM with LTV prophylaxis, underscoring the importance of personalized medicine. - Dose Effect of Antithymocyte Globulin or Post-transplant Cyclophosphamide in Haploidentical Peripheral Blood Stem Cell Transplantation: A Comparative Study.
Yosuke Nakaya; Hirohisa Nakamae; Hideki Nakasone; Hiroshi Okamura; Naonori Harada; Koji Kawamura; Seitaro Terakura; Yuta Hasegawa; Tetsuya Eto; Takahiro Fukuda; Nobuhiro Hiramoto; Koji Nagafuji; Shuichi Ota; Yumiko Maruyama; Toshiro Kawakita; Ken-Ichi Matsuoka; Noriko Doki; Tomohiko Kamimura; Toshihiko Ando; Takashi Akasaka; Yoshiko Atsuta; Junya Kanda
Transplantation and cellular therapy, 31, 8, 544.e1-544.e5, 26 Apr. 2025, [International Magazine]
English, Scientific journal - The impact of the SARS-CoV-2 pandemic on umbilical cord blood transplantation in Japan: insights from an interrupted time series analysis.
Nobuhiko Nakamura; Tetsuji Morishita; Hiromi Hayashi; Motohito Okabe; Hideki Nakasone; Naoyuki Uchida; Noriko Doki; Takahiro Fukuda; Satoshi Yoshihara; Masatsugu Tanaka; Tetsuya Nishida; Yuta Hasegawa; Ken-Ichi Matsuoka; Masashi Sawa; Tetsuya Eto; Makoto Onizuka; Yuta Katayama; Koji Kato; Fumihiko Ishimaru; Ken Tabuchi; Yoshiko Atsuta; Nobuhiro Kanemura; Takanori Teshima
Bone marrow transplantation, 60, 7, 964, 970, 17 Apr. 2025, [International Magazine]
English, Scientific journal, The SARS-CoV-2 pandemic disrupted healthcare systems worldwide, particularly affecting hematopoietic stem cell transplantation (HSCT) activities. Understanding the impact of the SARS-CoV-2 pandemic on transplant practices, especially in Japan, where cord blood transplantation (CBT) is prevalent, is crucial. A total of 40,444 allogeneic HSCT cases in Japan between 2011 and 2021 were examined using an interrupted time series analysis to assess the impact of COVID-19 on CBT utilization. Following the SARS-CoV-2 pandemic, CBT cases demonstrated a significant increase (11.06 [95% confidence interval (CI): 1.87 to 20.25] cases per month), whereas bone marrow transplantation cases decreased, by 10.74 cases per month (95% CI, -19.84 to -1.63 cases per month). Total HSCT cases remained stable with a level change of 5.47 cases per month (95% CI, -10.07 to 21.01 cases per month) and a trend change of -1.11 cases per month (95% CI, -2.22 to 0.004 cases per month). The interrupted time series analysis showed significantly increased CBT cases in Japan, highlighting its crucial role as an alternative transplant source during the pandemic. CBT offset the impact of the decrease in bone marrow transplantation and contributed to the maintenance of HSCT activity in Japan during the unprecedented crisis. - Improved post-transplant outcomes for elderly acute myeloid leukemia patients conditioned with FLU/BU4 rather than conventional MAC regimens.
Takuya Shimizu; Yasuyuki Arai; Tadakazu Kondo; Shingo Yano; Yoshimitsu Shimomura; Noriko Doki; Takahiro Fukuda; Tetsuya Nishida; Satoshi Takahashi; Shuichi Ota; Yoshinobu Kanda; Takuro Kuriyama; Naoki Kurita; Toshiro Kawakita; Yuta Hasegawa; Nobuhiro Hiramoto; Makoto Onizuka; Yoshiko Atsuta; Masamitsu Yanada
Bone marrow transplantation, 60, 6, 804, 810, 05 Apr. 2025, [International Magazine]
English, Scientific journal, It is uncertain whether FLU/BU4 regimens, classified as myeloablative conditioning (MAC), improve prognosis compared to conventional MAC regimens (conv-MAC) such as CY/TBI and BU/CY. We compared FLU/BU4 with conv-MAC among 6551 patients (FLU/BU4 905, conv-MAC 5646), including acute myeloid leukemia (AML) patients aged 16-59 who received a first allogeneic transplantation from the Japanese nationwide registry. The primary endpoint was overall survival (OS), while secondary endpoints were treatment-related mortality (TRM) and relapse at 3 years. Results indicated comparable OS for conv-MAC regimens among the entire cohort (3-year OS: FLU/BU4 50.4% vs. conv-MAC 55.4%, p < 0.001). Subgroup analysis focusing on elderly patients (aged 50-59) indicated that FLU/BU4 showed a statistically significant improvement in OS (47.0% vs. 42.8%, p = 0.036). Notably, for patients in this cohort transplanted at complete remission (CR), FLU/BU4 demonstrated a substantial advantage over conv-MAC with superior OS (HR 0.75, p = 0.046), lower TRM (HR 0.66, p = 0.035), and comparable relapse (HR 0.84, p = 0.390). These benefits were not observed in elderly patients transplanted at non-CR or in other age groups. In summary, our findings suggest that FLU/BU4 regimen, rather than conv-MAC, may be preferable in MAC-tolerant AML patients, aged 50-59 at CR status. This treatment improves survival by reducing TRM without increasing relapse risk. - Association of FLT3-ITD and NPM1 mutations with outcomes of allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
Masamitsu Yanada; Satoshi Yamasaki; Hiroki Hosoi; Shohei Mizuno; Kaito Harada; Noriko Doki; Shin-Ichiro Fujiwara; Nobuhiro Hiramoto; Yuta Hasegawa; Kazuya Ishiwata; Tetsuya Nishida; Noboru Asada; Takuma Suzuki; Mamiko Sakata-Yanagimoto; Naoyuki Uchida; Junya Kanda; Makoto Yoshimitsu; Yoshinobu Kanda; Takahiro Fukuda; Marie Ohbiki; Yoshiko Atsuta; Takaaki Konuma
Bone marrow transplantation, 60, 6, 894, 896, 05 Apr. 2025, [International Magazine]
English - 同種造血幹細胞移植後のカルシニューリン阻害剤投与時期がドナーT細胞疲弊および慢性GVHD発症に及ぼす影響の検討
千丈 創; 橋本 大吾; 塚本 しほり; 久保田 晋平; 伊藤 歩; 田中 喬; 一木 朝絵; 岡田 怜; 齋藤 祐美花; 宮島 徹; 李 文玉; 張 紫旋; 原田 晋平; 長谷川 祐太; 荒 隆英; 長谷川 嘉則; 稲本 賢弘; 村上 正晃; 福田 隆浩; 豊嶋 崇徳
日本輸血細胞治療学会誌, 71, 2, 333, 333, (一社)日本輸血・細胞治療学会, Apr. 2025
Japanese - 本邦の骨髄・末梢血幹細胞移植におけるGVHD予防としてのATG使用件数の年次推移
白鳥 聡一; 大引 真理恵; 土岐 典子; 福田 隆浩; 吉原 哲; 神田 善伸; 西田 徹也; 淺田 騰; 中前 博久; 長谷川 祐太; 熱田 由子; 豊嶋 崇徳
日本輸血細胞治療学会誌, 71, 2, 473, 473, (一社)日本輸血・細胞治療学会, Apr. 2025
Japanese - Significant detrimental impact of pre-transplant mogamulizumab on the post-transplant outcome with a short interval between the last mogamulizumab and transplantation.
Shigeo Fuji; Masahito Tokunaga; Koji Kato; Nobuaki Nakano; Takero Shindo; Junya Makiyama; Hidehiro Itonaga; Ayumu Ito; Tetsuya Eto; Jun Ishikawa; Yuta Hasegawa; Kenji Ishitsuka; Yukiyoshi Moriuchi; Shuichi Ota; Yasuo Mori; Youko Suehiro; Ken Takase; Yoshinobu Kanda; Makoto Onizuka; Takahiro Fukuda; Yoshiko Atsuta; Makoto Yoshimitsu
Bone marrow transplantation, 60, 4, 552, 554, Apr. 2025, [International Magazine]
English - Donor selection in T-cell-replete haploidentical donor peripheral blood stem cell transplantation.
Fumiya Wada; Makoto Iwasaki; Masahiro Hirayama; Koji Kawamura; Katsuji Kaida; Noriko Doki; Hirohisa Nakamae; Yuta Hasegawa; Takahiro Fukuda; Tetsuya Eto; Nobuhiro Hiramoto; Yumiko Maruyama; Koji Nagafuji; Shuichi Ota; Jun Ishikawa; Toshihiko Ando; Tatsuo Ichinohe; Yoshiko Atsuta; Hideki Nakasone; Junya Kanda
Leukemia, 39, 4, 951, 961, Apr. 2025, [International Magazine]
English, Scientific journal, The effects of donor characteristics on outcomes after T-cell-replete (TCR) haploidentical donor peripheral blood stem cell transplantation (PBSCT) with post-transplant cyclophosphamide (PTCy) or low-dose antithymocyte globulin (ATG) remain unclear. We evaluated the impact in 1,677 patients who received a PTCy protocol (PTCy-haplo; n = 1,107) or low-dose ATG protocol (ATG-haplo; n = 570). A low CD34+ cell dose (<4 ×106/kg) was the only donor characteristic associated with worse overall survival (OS) after PTCy-haplo (adjusted hazard ratios [aHR] = 1.49, P = 0.008), whereas increasing donor age by decade (aHR = 1.12, P = 0.008) and human leukocyte antigen 2-3 antigen mismatches (aHR = 1.46, P = 0.010), compared to HLA 0-1 antigen mismatches, were associated with worse OS after ATG-haplo. Increasing donor age was associated with a high risk of grade III-IV acute GVHD both after PTCy-haplo (HR: 1.32, P = 0.009) and ATG-haplo (HR: 1.22, P = 0.006). Offspring donors had better relapse-free survival and GVHD-free relapse-free survival than sibling donors after ATG-haplo. Our data highlights the donor characteristics associated with improved transplant outcomes after TCR haploidentical donor PBSCT with PTCy or low-dose ATG. - Clinical effects of granulocyte colony-stimulating factor administration and the timing of its initiation on allogeneic hematopoietic cell transplantation outcomes for myelodysplastic syndrome.
Takaaki Konuma; Machiko Fujioka; Kyoko Fuse; Hiroki Hosoi; Yosuke Masamoto; Noriko Doki; Naoyuki Uchida; Masatsugu Tanaka; Masashi Sawa; Tetsuya Nishida; Jun Ishikawa; Noboru Asada; Hirohisa Nakamae; Yuta Hasegawa; Makoto Onizuka; Takeshi Maeda; Takahiro Fukuda; Koji Kawamura; Yoshinobu Kanda; Marie Ohbiki; Yoshiko Atsuta; Hidehiro Itonaga
Transplantation and cellular therapy, 31, 6, 388.e1-388.e14, 17 Mar. 2025, [International Magazine]
English, Scientific journal, Granulocyte colony-stimulating factor (G-CSF) accelerates neutrophil recovery after allogeneic hematopoietic cell transplantation (HCT). However, the optimal use of G-CSF and the timing of its initiation after allogeneic HCT for myelodysplastic syndrome (MDS) according to graft type have not been determined. This retrospective study aimed to investigate the effects of using G-CSF administration and the timing of its initiation on transplant outcomes in adult patients with MDS undergoing allogeneic HCT. Using Japanese registry data, we retrospectively investigated the effects of G-CSF administration and the timing of its initiation on transplant outcomes among 4140 adults with MDS after bone marrow transplantation (BMT), peripheral blood stem cell transplantation (PBSCT), or single-unit cord blood transplantation (CBT) between 2013 and 2022. Multivariate analysis showed that early (days 0 to 4) and late (days 5 to 10) G-CSF administration significantly accelerated neutrophil recovery compared with no G-CSF administration following BMT, PBSCT, and CBT, but there was no benefit of early G-CSF initiation for early neutrophilic recovery regardless of graft type. Late G-CSF initiation was significantly associated with a higher risk of overall chronic GVHD following PBSCT (hazard ratio [HR], 1.63; 95% confidence interval [CI], 1.18 to 2.24; P = .002) and CBT (HR, 2.09; 95% CI, 1.21 to 3.60; P = .007) compared with no G-CSF administration. Late G-CSF initiation significantly improved OS compared with no G-CSF administration only following PBSCT (HR, 0.74; 95% CI, 0.58 to 0.94; P = .015). However, G-CSF administration and the timing of its initiation did not affect acute GVHD, relapse, or non-relapse mortality, irrespective of graft type. These results suggest that G-CSF administration significantly accelerated neutrophil recovery after BMT, PBSCT, and CBT, but increased risk of overall chronic GVHD after PBSCT and CBT. However, the effect of early and late G-CSF initiation on transplant outcomes needs further study in adult patients with MDS. - Impact of Haplo-Donor Age on Transplant Outcomes: A Comparative Analysis of Haploidentical vs Cord Blood Transplantation.
Takashi Nagayama; Shin-Ichiro Fujiwara; Satoshi Nishiwaki; Fumiya Wada; Naoyuki Uchida; Masatsugu Tanaka; Mamiko Sakata-Yanagimoto; Makoto Onizuka; Kazuya Ishiwata; Yuta Hasegawa; Shuichi Ota; Noriko Doki; Hirohisa Nakamae; Tetsuya Nishida; Toshiro Kawakita; Masashi Sawa; Masahito Tokunaga; Fumihiko Ishimaru; Takahiro Fukuda; Yoshinobu Kanda; Yoshiko Atsuta; Hideki Nakasone
Blood advances, 9, 13, 3226, 3237, 14 Mar. 2025, [International Magazine]
English, Scientific journal, Allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-matched donors is the gold standard. However, haploidentical stem cell transplantation using posttransplant cyclophosphamide (PTCY-haplo) and cord blood transplants (CBTs) are alternatives when HLA-matched donors are unavailable. Using the Japanese Registry data, we evaluated the impact of haploidentical donor age on posttransplant outcomes by comparing PTCY-haplo and CBT. We analyzed data for 5,161 patients aged 16-70 who received their first HSCT for acute leukemia, myelodysplastic syndrome, or chronic myeloid leukemia. Haploidentical donors were categorized as "younger" (<40 years) or "older" (≥40 years), and the patients were divided into younger (<50 years) and older (≥50 years) cohorts. In the older cohort, PTCY-haplo from younger donors had better overall survival (OS) (55.5% vs. 50.8%, P = 0.006), lower nonrelapse mortality (NRM) (17.3% vs. 28.6%, P < 0.001), and higher relapse rates (33.0% vs. 24.9%, P = 0.017) compared with CBT. PTCY-haplo from older donors had comparable OS (44.1% vs. 50.8%, P = 1.00), NRM (27.3% vs. 28.6%, P = 1.00), and relapse (29.2% vs. 24.9%, P = 0.90) to CBT. In the younger cohort, PTCY-haplo from younger and older donors showed comparable OS, NRM, and relapse to CBT. Compared to PTCY-haplo, cumulative incidence of acute graft-versus host disease (GVHD) was higher in CBT, regardless of donor age, in the older cohort. However, acute GVHD was lower in PTCY-haplo from younger donors in the younger cohort compared with CBT. PTCY-haplo from younger donors to older patients offers better clinical outcomes compared with CBT. - Chronic graft-versus-host disease myelitis successfully treated with rituximab.
Emi Yokoyama; Yuta Hasegawa; Kentaro Wakaki; Touma Suzuki; Sayaka Kajikawa; Minoru Kanaya; Koh Izumiyama; Makoto Saito; Masanobu Morioka; Jun Nagai; Tomoe Ichiki; Ryo Kikuchi; Satomi Okada; Hiroyuki Ohigashi; Hideki Goto; Masahiro Onozawa; Daigo Hashimoto; Akio Mori; Takanori Teshima; Takeshi Kondo
International journal of hematology, 121, 5, 712, 717, 31 Jan. 2025, [Domestic magazines]
English, Scientific journal, Chronic graft-versus-host disease (cGVHD) is a major serious complication after allogeneic stem-cell transplantation (allo-HSCT), and often mimics autoimmune diseases. Central nervous system (CNS) symptoms are rare manifestations of cGVHD, and are difficult to diagnose. CNS manifestations of cGVHD were discussed in the 2020 National Institutes of Health cGVHD Consensus Project as one of the "atypical cGVHD manifestations" with involvement of various organ systems other than classical cGVHD organs. We experienced a case of myelitis after allo-HSCT diagnosed as cGVHD of the CNS. The neurological symptoms progressed after corticosteroid pulse therapy, resulting in severe paralysis and paresthesia of the lower extremities. The clinical course and magnetic resonance imaging findings showed some similarities with multiple sclerosis. We decided to use rituximab after the patient became refractory to corticosteroids because rituximab has been reported to be effective in multiple sclerosis by suppressing B cells on both sides of the blood-brain barrier. Rituximab was effective for the neurologic symptoms in our case. In atypical cGVHD, treatments used in corresponding autoimmune diseases may be reasonable and effective. - Different impacts of granulocyte colony-stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type.
Takaaki Konuma; Kazuaki Kameda; Kaoru Morita; Tadakazu Kondo; Fumihiko Kimura; Hideki Nakasone; Fumihiko Ouchi; Naoyuki Uchida; Masatsugu Tanaka; Tetsuya Nishida; Takahiro Fukuda; Yuta Hasegawa; Mamiko Sakata-Yanagimoto; Makoto Onizuka; Masashi Sawa; Shuichi Ota; Noboru Asada; Shin-Ichiro Fujiwara; Satoshi Yoshihara; Fumihiko Ishimaru; Makoto Yoshimitsu; Yoshinobu Kanda; Marie Ohbiki; Yoshiko Atsuta; Masamitsu Yanada
American journal of hematology, 100, 1, 66, 77, Jan. 2025, [International Magazine]
English, Scientific journal, We retrospectively evaluated the impacts of using granulocyte colony-stimulating factor (G-CSF) and its timing on posttransplant outcomes for 9766 adults with acute myeloid leukemia (AML) between 2013 and 2022 using a Japanese database. We separately evaluated three distinct cohorts based on graft type: 3248 received bone marrow transplantation (BMT), 3066 received peripheral blood stem cell transplantation (PBSCT), and 3452 received single-unit cord blood transplantation (CBT). Multivariate analysis showed that G-CSF administration significantly accelerated neutrophil recovery after BMT, PBSCT, and CBT. However, it was associated with a higher risk of grades II-IV acute graft-versus-host disease (GVHD) across all graft types. Moreover, an increased incidence of overall chronic GVHD was observed with G-CSF administration in BMT and CBT patients, but not in PBSCT patients. G-CSF administration significantly improved overall survival (OS) and leukemia-free survival (LFS) only following CBT. Regarding the timing of G-CSF, in comparison with late initiation of G-CSF (Days 5-10), early initiation (Days 0-4) did not provide benefits for hematopoietic recovery regardless of graft type. In contrast, late initiation was significantly associated with a lower risk of grades II-IV acute GVHD and better OS and LFS in CBT patients. These data demonstrated that G-CSF administration accelerated neutrophil recovery and increased the risk of grades II-IV acute GVHD across all graft types, but significantly improved survival outcomes but only following CBT. Therefore, routine use of G-CSF should be considered for CBT in adult patients with AML. - Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)/FUS::ERG.
Satoshi Mitsuyuki; Yoshimitsu Shimomura; Hiroki Mizumaki; Masamitsu Yanada; Shohei Mizuno; Naoyuki Uchida; Noriko Doki; Ayumu Ito; Masatsugu Tanaka; Tetsuya Nishida; Yuta Katayama; Satoshi Yoshihara; Tetsuya Eto; Satoru Takada; Shuichi Ota; Masako Toyosaki; Yuta Hasegawa; Hirohisa Nakamae; Koji Kawamura; Makoto Onizuka; Takahiro Fukuda; Marie Ohbiki; Yoshiko Atsuta; Takaaki Konuma
Leukemia, 39, 2, 495, 498, 10 Dec. 2024, [International Magazine]
English, Scientific journal - Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide versus HLA-matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia.
Makoto Moriguchi; Hirohisa Nakamae; Mitsutaka Nishimoto; Junichi Sugita; Masamitsu Yanada; Tomomi Toubai; Yuta Hasegawa; Masayuki Hino; Tetsuya Nishida; Naoki Kurita; Masashi Sawa; Takahiro Fukuda; Atsushi Jinguji; Shuichi Ota; Ken-Ichi Matsuoka; Tetsuya Eto; Nobuhiro Hiramoto; Toshihiko Ando; Koji Kawamura; Yoshinobu Kanda; Yoshiko Atsuta; Marie Ohbiki; Hideki Nakasone; Takaaki Konuma
British journal of haematology, 205, 6, 2376, 2386, Dec. 2024, [International Magazine]
English, Scientific journal, HLA-haploidentical haematopoietic cell transplantation with post-transplant cyclophosphamide (PTCy-haplo) is emerging as an effective alternative due to donor availability and safety. We conducted a nationwide retrospective study comparing the outcomes of PTCy-haplo with both anti-thymocyte globulin (ATG)-free and ATG-administered matched unrelated donors (MUD) transplantation, using peripheral blood stem cells as the first transplantation for acute myeloid leukaemia (AML). Our study showed a lower and slower haematopoietic recovery and a higher incidence of infection-related deaths after PTCy-haplo than after MUD transplantation. In addition, we revealed an increased risk of acute and chronic graft-versus-host disease (GVHD) in ATG-free MUD transplantation in comparison to PTCy-haplo. For grades III-IV acute GVHD, the hazard ratio (HR) was 2.71 (95% CI, 1.46-5.01), and for extensive chronic GVHD, the HR was 3.11 (95% CI, 2.07-4.68). There was no significant difference regarding overall survival amongst the groups. In addition, GVHD-free relapse-free survival (GRFS) was lower in ATG-free MUD transplantation than in PTCy-haplo (HR, 1.46; 95% CI, 1.17-1.82). Notably, ATG-administered MUD transplantation showed no significant difference in GRFS from PTCy-haplo, negating the advantage of PTCy. Our results suggest that PTCy-haplo could be viable for AML patients without an HLA-matched related donor. - Comparison of Nonrelapse Mortality After Haploidentical Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide Versus Single Umbilical Cord Blood Transplantation in Hematologic Disease.
Kaito Harada; Junya Kanda; Masahiro Hirayama; Fumiya Wada; Naoyuki Uchida; Masatsugu Tanaka; Hirohisa Nakamae; Masahito Tokunaga; Kazuya Ishiwata; Makoto Onizuka; Yuta Hasegawa; Takahiro Fukuda; Tetsuya Eto; Naoki Kurita; Toshiro Kawakita; Atsushi Jinguji; Fumihiko Ishimaru; Yoshiko Atsuta; Hideki Nakasone
Transplantation and cellular therapy, 31, 2, 103.e1-103.e13, 26 Nov. 2024, [International Magazine]
English, Scientific journal, Unrelated cord blood transplantation (UCBT) and haploidentical transplantation using posttransplant cyclophosphamide (PTCy-haplo) are alternatives for patients lacking a human leukocyte antigen-matched donor. CD34+ cell counts in cord blood affect transplantation outcomes, particularly nonrelapse mortality (NRM). The primary objective of this study was to compare the transplantation outcomes after UCBT and PTCy-haplo focusing on CD34+ cell counts in cord blood. This retrospective study used data from 2014 to 2020 from a Japanese nationwide database. UCBT cases were divided into those with UCBT with higher (UCB-H; ≥.84 × 105/kg) and lower (UCB-L; <.84 × 105/kg) CD34+ cell counts, depending on the median CD34+ cell count. The study cohort comprised cases of PTCy-haplo (n = 1142), UCB-H (n = 3185), and UCB-L (n = 3172). In the multivariate analysis, neutrophil engraftment was significantly better in the PTCy-haplo than in the UCB-H (hazard ratio [HR], .64; 95% confidence interval [CI], .57 to .70; P < .001) and UCB-L groups (HR, .45; 95% CI, .41 to .50; P < .001). The UCB-H group showed similar NRM (HR, 1.19, 95% CI, 1.00 to 1.43, P = .051) and OS (HR, 1.05, 95% CI, .94 to 1.18, P = .38) compared with PTCy-haplo, whereas UCB-L was significantly associated with poor NRM (HR, 1.35, 95% CI, 1.13 to 1.61, P = .001) and OS (HR, 1.13, 95% CI, 1.01 to 1.26, P = .038). In contrast, the UCB-H (HR, .86; 95% CI, .75 to .98; P = .027) and UCB-L groups (HR, .80; 95% CI, .70 to .92; P = .001) were associated with lower relapse rate. Regarding the graft-versus-host disease (GVHD), the UCB-H and UCB-L groups were identified as significant risk factors for the development of grade II-IV acute GVHD (UCB-H: HR, 1.73; 95% CI, 1.51 to 1.99; P < .001; UCB-L: HR, 1.55; 95% CI, 1.35 to 1.78; P < .001) and grade III-IV acute GVHD (UCB-H: HR, 2.28; 95% CI, 1.78 to 2.91; P < .001; UCB-L: HR, 1.85; 95% CI, 1.44 to 2.37; P < .001), but neither were associated with the incidence of all-grade GVHD (UCB-H: HR, 1.12; 95% CI, .95 to 1.32; P = .16; UCB-L: HR, 1.08; 95% CI, .91 to 1.27; P = .37) or extensive chronic GVHD (UCB-H: HR, .86; 95% CI, .68 to 1.09; P = .21; UCB-L: HR, .88; 95% CI, .69 to 1.12; P = .31). Furthermore, higher NRM in UCB-L was attributed to higher infection-related mortality (HR, 1.50; 95% CI, 1.15 to 1.95; P = .003) but not GVHD-related mortality (HR, 1.15; 95% CI, .82 to 1.62; P = .43), whereas UCB-H was not a significant risk factor for both infection-related mortality (HR, 1.29; 95% CI, .99 to 1.69; P = .06) and GVHD-related mortality (HR, 1.28; 95% CI, .90 to 1.80; P = .16). UCB-H offered similar NRM and OS to PTCy-haplo, whereas UCB-L had worse outcomes. Our results can provide useful information for optimal donor selection. - Machine learning evaluation of intensified conditioning on haematopoietic stem cell transplantation in adult acute lymphoblastic leukemia patients.
Tomoyasu Jo; Kosuke Inoue; Tomoaki Ueda; Makoto Iwasaki; Yu Akahoshi; Satoshi Nishiwaki; Hiroki Hatsusawa; Tetsuya Nishida; Naoyuki Uchida; Ayumu Ito; Masatsugu Tanaka; Satoru Takada; Toshiro Kawakita; Shuichi Ota; Yuta Katayama; Satoshi Takahashi; Makoto Onizuka; Yuta Hasegawa; Keisuke Kataoka; Yoshinobu Kanda; Takahiro Fukuda; Ken Tabuchi; Yoshiko Atsuta; Yasuyuki Arai
Communications medicine, 4, 1, 247, 247, 25 Nov. 2024, [International Magazine]
English, Scientific journal, BACKGROUND: The advantage of intensified myeloablative conditioning (MAC) over standard MAC has not been determined in haematopoietic stem cell transplantation (HSCT) for adult acute lymphoblastic leukemia (ALL) patients. METHODS: To evaluate heterogeneous effects of intensified MAC among individuals, we analyzed the registry database of adult ALL patients between 2000 and 2021. After propensity score matching, we applied a machine-learning Bayesian causal forest algorithm to develop a prediction model of individualized treatment effect (ITE) of intensified MAC on reduction in overall mortality at 1 year after HSCT. RESULTS: Among 2440 propensity score-matched patients, our model shows heterogeneity in the association between intensified MAC and 1-year overall mortality. Individuals in the high-benefit group (n = 1220), defined as those with ITEs greater than the median, are more likely to be younger, male, and to have higher refined Disease Risk Index (rDRI), T-cell phenotype, and grafts from related donors than those in the low-benefit group (n = 1220). The high-benefit approach (applying intensified MAC to individuals in the high-benefit group) shows the largest reduction in overall mortality at 1 year (risk difference [95% confidence interval], +5.94 percentage points [0.88 to 10.51], p = 0.011). In contrast, the high-risk approach (targeting patients with high or very high rDRI) does not achieve statistical significance (risk difference [95% confidence interval], +3.85 percentage points [-1.11 to 7.90], p = 0.063). CONCLUSIONS: These findings suggest that the high-benefit approach, targeting patients expected to benefit from intensified MAC, has the capacity to maximize HSCT effectiveness using intensified MAC. - Reappraising the prognostic relevance of cytogenetic risk in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.
Shohei Mizuno; Hiroki Hosoi; Akiyoshi Takami; Takahito Kawata; Noriko Doki; Wataru Takeda; Masatsugu Tanaka; Tetsuya Nishida; Naoyuki Uchida; Yuta Hasegawa; Masashi Sawa; Shuichi Ota; Makoto Onizuka; Hirohisa Nakamae; Noboru Asada; Takahiro Fukuda; Makoto Yoshimitsu; Yoshinobu Kanda; Marie Ohbiki; Yoshiko Atsuta; Takaaki Konuma; Masamitsu Yanada
Annals of hematology, 103, 12, 5903, 5913, 19 Nov. 2024, [International Magazine]
English, Scientific journal, This study aimed to investigate the prognostic relevance of cytogenetic risk in 9826 adults with acute myeloid leukemia (AML) who underwent allogeneic hematopoietic cell transplantation (HCT) during the first or second complete remission. The 5-year probabilities of overall survival (OS) were 66%, 61%, and 47% (P < 0.001), the cumulative incidences of relapse were 14%, 19%, and 32% (P < 0.001), and the cumulative incidences of non-relapse mortality (NRM) were 23%, 23%, and 25% (P = 0.208) in patients with favorable (n = 1418), intermediate (n = 6747), and poor cytogenetic risk (n = 1661), respectively. The significant effect of cytogenetic risk on OS was strong in all subgroups stratified by age, sex, performance status, disease status, donor type, conditioning intensity, graft-versus-host disease prophylaxis, and transplantation period (P < 0.001 for all). The evaluation of trends in posttransplant outcomes for patients in each cytogenetic risk category indicated that the risk of relapse declined in patients with favorable and intermediate cytogenetics and that the risk of NRM decreased in those with intermediate and poor cytogenetics. Therefore, patients with intermediate cytogenetics experienced the best OS improvement. These results confirm cytogenetic risk as a universal prognostic factor in patients with AML undergoing allogeneic HCT while highlighting the requirement for further improvements in posttransplant OS by reducing NRM in patients with favorable cytogenetics and by reducing relapse in patients with poor cytogenetics. - Kinetics of Recipients with Thrombocytopenia and Its Impact on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study
Naoki Kurita; Kazushi Maruo; Fumihiko Kimura; Yachiyo Kuwatsuka; Toshihiro Matsukawa; Takaaki Konuma; Shinichi Kobayashi; Mamiko Sakata-Yanagimoto; Noriko Doki; Masatsugu Tanaka; Naoyuki Uchida; Tetsuya Nishida; Masashi Sawa; Yuta Hasegawa; Hirohisa Nakamae; Shuichi Ota; Makoto Onizuka; Takahiro Fukuda; Fumihiko Ishimaru; Ken Tabuchi; Yoshiko Atsuta; Junya Kanda; Hideki Nakasone
Blood, 144, Supplement 1, 2121, 2121, American Society of Hematology, 05 Nov. 2024
Scientific journal, Background: Thrombocytopenia is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HCT), which can lead to increased mortality and impaired quality of life with prolonged transfusion dependency and high risk of bleeding. However, it is not clear how many patients survive without sufficient platelet recovery after allo-HCT. Here, we visualized the kinetics of neutrophil and platelet recovery and the impact on outcomes using multistate models with transplant registry data. We also compared the effects of different graft sources.
Methods: We analyzed Japanese nationwide registry data of adult patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in complete remission who underwent first allo-HCT from 2010 to 2022. Second transplantation was treated as a censoring event. Transitional changes of the population with neutrophil <0.5×109/L (state 0), neutrophil ≥0.5×109/L and platelet <20×109/L (state 1), 20×109/L≤ platelet <50×109/L (state 2), and platelet ≥50×109/L (state 3), death, relapse, and non-relapse mortality (NRM) were estimated by multistate model analysis using transition probability plot and proportional transition hazard model. The effects of hematopoietic recovery on mortality, relapse, and NRM were estimated by Simon-Makuch plot and proportional hazard model with time-dependent covariates. Influences of the background factors (age, recipient sex, performance status, comorbidity, diagnoses, disease risk, graft sources, ABO major mismatch, conditioning intensity, and year of transplantation) were adjusted.
Results: A total of 9105 patients (5802 AML and 3303 ALL) were extracted from the database. The number of the transplant sources were: 2398 HLA-matched unrelated bone marrow (uBM), 782 HLA-matched related BM (rBM), 326 HLA-matched unrelated peripheral-blood stem cells (uPB), 1283 HLA-matched rPB, 622 HLA-haploidentical PB (Haplo), and 3694 single-unit cord blood (CB). The median age at allo-HCT was 49 (range, 16-85) years. Neutrophil ≥0.5×109/L at day 60, platelet ≥20×109/L and ≥50×109/L at day 100 were 99%, 91%, and 85% in uBM, 99%, 96%, and 92% in rBM, 99%, 95%, and 90% in uPB, 99%, 96%, and 93% in rPB, 98%, 91%, and 84% in Haplo, and 94%, 87%, and 82% in CB, respectively. Multistate model analysis with the entire patient population showed that the proportions in states 0, 1, 2, 3, relapse, and NRM were 1.4%, 9.9%, 7.4%, 77%, 1.3%, and 3.4% at day 60; and 0.1%, 3.8%, 4.3%, 80%, 5.4%, and 6.6% at day 120, respectively. Patients surviving without adequate platelet recovery (the sum of states 0, 1, and 2) was significantly higher in CB (25%) than in other sources (11-13%) at day 60. Interestingly, the difference became marginal at day 120 (8.3% in CB, and 6.5-8.7% in other sources). Survival probabilities by the Simon-Makuch method in states 0, 1, 2, and 3 were 83%, 93%, 98%, and 100% at day 60, and 44%, 71%, 91%, and 98% at day 120, respectively (P<0.001). Time-dependent covariate analysis showed that the hazard ratios (HRs) of the patients in states 0, 1, and 2 (vs. state 3) were 40, 5.3, and 2.4 for mortality; 57, 7.6, and 3.1 for NRM (all P<0.001), respectively, after adjustment for the background factors. The NRM causes of patients in states 1 and 2 were infection (24%), organ failure (19%), SOS/TMA (12%), and acute GVHD (10%), with the proportion of SOS/TMA and acute GVHD being more than double that of patients in state 3. Multistate model analysis showed that although the transition probabilities (TPs) to mortality from states 1 and 2 were higher in CB (HR 1.4 and 1.7, respectively) compared with uBM, the TP to mortality from state 3 was significantly lower in CB (HR 0.86; P=0.008; vs. uBM) with lower trends for both relapse and NRM.
Conclusions: In this largest retrospective study on hematopoietic recovery to date, the kinetics of survivors without platelet recovery and the detrimental impact of thrombocytopenia on overall mortality and NRM were clearly demonstrated. SOS/TMA and acute GVHD had a greater influence on the NRM of thrombocytopenic patients. Although the platelet recovery was delayed in CB, the proportion of survivors with thrombocytopenia at day 120 was comparable to other sources. The higher risk for mortality in CB was transient, and the risk in CB became less than in uBM after platelet recovery (≥50×109/L). This analysis provides baseline data for future studies of hematopoietic recovery. - Comparing de novo chronic myeloid leukemia in blastic phase with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation.
Yosuke Okada; Noriaki Tachi; Yutaka Shimazu; Makoto Murata; Satoshi Nishiwaki; Yasushi Onishi; Atsushi Jinguji; Naoyuki Uchida; Masatsugu Tanaka; Yuta Hasegawa; Ayumu Ito; Shinichi Kako; Tetsuya Nishida; Koichi Onodera; Masashi Sawa; Hirohisa Nakamae; Masako Toyosaki; Yoshinobu Kanda; Makoto Onizuka; Takahiro Fukuda; Marie Ohbiki; Yoshiko Atsuta; Yasuyuki Arai; Takayoshi Tachibana
Cancer, 131, 1, e35627, 04 Nov. 2024, [International Magazine]
English, Scientific journal, BACKGROUND: De novo chronic myeloid leukemia in blastic phase (CML-BP) showing lymphoid immunophenotype mimics Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL). Although upfront allogeneic hematopoietic cell transplantation (HCT) is considered in both diseases, it is not yet clear whether the transplant outcomes are also similar. METHODS: Using a registry database, the transplant outcomes between de novo CML-BP and Ph-positive ALL in negative-minimal residual disease (MRD), positive MRD, and nonremission cohorts were compared, respectively. All of the included patients had received tyrosine kinase inhibitor therapy before HCT and underwent HCT between 2002 and 2021. Regarding Ph-positive ALL, patients with p210 transcripts were excluded because there was concern that this group might include patients with de novo CML-BP. RESULTS: Although most of the outcomes were comparable, in patients with positive MRD at HCT, de novo CML-BP was significantly associated with superior disease-free survival (DFS) (hazard ratio [HR] 0.6, p = .0032), overall survival (HR 0.66, p = .027), and a lower risk of relapse (HR 0.48, p = .0051). In subgroup analyses, BCR::ABL1 mutation status had a significant interaction with the disease (p for interaction = .0027). De novo CML-BP seemed to be associated with superior disease-free survival in a BCR::ABL1 mutation-positive cohort, whereas this association was not observed in a mutation-negative cohort. CONCLUSIONS: Considering previous reports that showed inferior outcomes for de novo CML-BP compared to Ph-positive ALL, the data suggested that allogeneic HCT could overcome the poor prognosis of de novo CML-BP. These findings highlight the importance of distinguishing de novo CML-BP from Ph-positive ALL. - An abnormal increase in CD26(-)CD28(-) cytotoxic effector CD4 and CD8 T cell populations in patients with systemic lupus erythematosus.
Ryo Hatano; Hayato Nakamura; Ayako Yamamoto; Haruna Otsuka; Takumi Itoh; Nao Hosokawa; Jinghui Yu; Sedigheh Ranjbar; Yuta Hasegawa; Tsutomu Sato; Nam H Dang; Kei Ohnuma; Shinji Morimoto; Iwao Sekigawa; Tomonori Ishii; Chikao Morimoto
International immunology, 09 Oct. 2024, [International Magazine]
English, Scientific journal, CD26 is a human T cell costimulatory molecule as well as a T cell subset marker, and increase of CD26+ T cells in inflamed tissues and peripheral blood has been reported in diverse autoimmune diseases. In contrast, our group has previously shown that levels of circulating CD26+ T cells are decreased in patients with systemic lupus erythematosus (SLE), although the role of reduced CD26 T cell surface expression in SLE pathology remains to be elucidated. In the present study, we conducted CD26-based T cell subset analyses utilizing peripheral blood mononuclear cells from 57 SLE patients and 31 healthy adult volunteers. We show that the increase in CD26(-) T cell population reflects the abnormal expansion of CD26(-)CD28(-) cytotoxic subsets of both CD8 T cells and CD4 T cells in SLE patients. Single cell RNA sequencing analysis of the CD26(-)CD28(-) CD4 and CD8 T cell populations reveals unique characteristics with similarities to natural killer T cells. In addition, the level of CD26(-)CD28(-) T cells is increased in some active stage SLE patients with renal manifestation. Meanwhile, effect of prednisolone treatment on these populations varies from patient to patient, with levels of these cytotoxic effector populations still being elevated in some inactive stage SLE patients. Taken together, our data suggest that analysis of these populations in SLE may be a useful tool to classify this markedly heterogeneous condition. - 移植後大量シクロホスファミドによる免疫寛容導入におけるカルシニューリン阻害薬開始時期の重要性
千丈 創; 橋本 大吾; 塚本 しほり; 久保田 晋平; 伊藤 歩; 田中 喬; 一木 朝絵; 岡田 怜; 齋藤 祐美花; 宮島 徹; 李 文玉; 張 紫旋; 原田 晋平; 長谷川 祐太; 荒 隆英; 長谷川 嘉則; 稲本 賢弘; 村上 正晃; 福田 隆浩; 豊嶋 崇徳
日本血液学会学術集会, 86回, O1, 4, (一社)日本血液学会, Oct. 2024
English - GVHD targets organoid-forming bile duct stem cells via a TGF-β-dependent manner.
Yuta Hasegawa; Daigo Hashimoto; Zixuan Zhang; Toru Miyajima; Yumika Saito; Wenyu Li; Ryo Kikuchi; Hajime Senjo; Tomoko Sekiguchi; Takahiro Tateno; Xuanzhong Chen; Emi Yokoyama; Shuichiro Takahashi; Hiroyuki Ohigashi; Takahide Ara; Eiko Hayase; Isao Yokota; Takanori Teshima
Blood, 144, 8, 904, 913, 21 Jun. 2024, [Lead author], [International Magazine]
English, Scientific journal, Graft-versus-host disease (GVHD) is a major life-threatening complication that occurs after allogeneic hematopoietic cell transplantation (HCT). While adult tissue stem cells have been identified as targets of GVHD in the skin and gut, their role in hepatic GVHD is yet to be clarified. In the current study, we explored the fate of bile duct stem cells (BDSCs), capable of generating liver organoids in vitro, during hepatic GVHD after allogeneic HCT. We observed a significant expansion of biliary epithelial cells (BECs) upon injury early after allogeneic HCT. Organoid-forming efficiency from the bile duct was also significantly increased early after allogeneic HCT. Subsequently, the organoid-forming efficiency from bile ducts was markedly decreased in association with the reduction of BECs and the elevation of plasma concentrations of bilirubin, suggesting that GVHD targets BDSCs and impairs the resilience of BECs. The growth of liver organoids in the presence of liver-infiltrating mononuclear cells from allogeneic recipients, but not from syngeneic recipients, significantly reduced in a TGF--dependent manner. Administration of SB-431542, an inhibitor of TGF-β signaling, from day 14 to day 28 protected organoid-forming BDSCs against GVHD and mitigated biliary dysfunction after allogeneic HCT, suggesting that BDSCs are a promising therapeutic target for hepatic GVHD. - Acute onset of constrictive pericarditis due to acute myelomonocytic leukemia: A case and literature review.
Naoki Kosaka; Takanori Uchiyama; Masahiro Onozawa; Jun Nagai; Jiro Koya; Suguru Ishizaka; Toshiyuki Nagai; Yohei Ikebe; Kenjiro Kato; Zen-Ichi Tanei; Jun Sakakibara-Konishi; Yuta Hasegawa; Hiroyuki Ohigashi; Hideki Goto; Daigo Hashimoto; Hideki Ujiie; Satoshi Hirano; Satoshi Konno; Toshihisa Anzai; Koji Taniguchi; Shinya Tanaka; Takanori Teshima
Internal medicine (Tokyo, Japan), 63, 24, 3359, 3365, 16 Apr. 2024, [Peer-reviewed], [Domestic magazines]
English, Scientific journal, We herein present a fatal case of constrictive pericarditis (CP) due to acute myelomonocytic leukemia (AMML) in a patient who initially complained of an acute onset of chest pain two days after COVID-19 vaccination. An autopsy revealed pericardial infiltration of leukemic cells. CP is rarely associated with leukemia and only 14 cases have been reported in the literature. The etiology of CP in previous reports included leukemic infiltration, graft-versus-host disease, drug-induced, post-radiation, autoimmune, and otherwise unidentified. This case indicates that leukemic infiltration can cause CP and that clinicians should include leukemia in the differential diagnosis of CP. - Efficacy and Safety of Single-dose Pegfilgrastim for CD34 + Cell Mobilization in Healthy Volunteers: A Phase 2 Study.
Hideki Goto; Junichi Sugita; Yuta Hasegawa; Koji Hayasaka; Kana Sunagoya; Rie Hatase; Mutsumi Nishida; Yuki Ichihashi; Mitsuhiko Odera; Hajime Senjo; Shota Yokoyama; Takahide Ara; Souichi Shiratori; Tomoyuki Endo; Masayuki Hino; Yoshinobu Maeda; Masashi Sawa; Norihiro Sato; Takanori Teshima
Transplantation, 108, 4, 996, 1003, 01 Apr. 2024, [International Magazine]
English, Scientific journal, BACKGROUND: Pegfilgrastim, a long-acting form of granulocyte-colony stimulating factor, with a convenient single-injection dosage, is being investigated for peripheral blood stem cell (PBSC) mobilization in healthy volunteers. However, data on the adequate dose of pegfilgrastim for PBSC mobilization are limited. This phase 2, single-arm study evaluated the efficacy and safety of pegfilgrastim for PBSC mobilization in healthy volunteers. METHODS: The study comprised 2 phases: pilot (steps 1-3, dose escalation, a single subcutaneous dose of 3.6, 7.2, and 10.8 mg pegfilgrastim, respectively) and evaluation (step 4, efficacy and safety assessments). The primary endpoint was the proportion of subjects who achieved mobilization of ≥20 × 10 6 /L cluster of differentiation 34 positive (CD34 + ) cells. RESULTS: Thirty-five subjects (6 each in steps 1 and 2 and 23 in step 4) were included. In the pilot phase, step 3 with a 10.8 mg dose was not conducted due to favorable outcomes in step 2 (desired CD34 + cell count), at 7.2 mg pegfilgrastim, which was identified as the optimal dose for the evaluation phase. In the evaluation phase, successful CD34 + mobilization was achieved in all 23 subjects. The mean peripheral blood CD34 + cells count peaked on day 5. Back pain, thrombocytopenia, transient elevations of alkaline phosphatase, and lactate dehydrogenase were the most common adverse events. All adverse events were mild, and none led to study discontinuation. CONCLUSIONS: A single-dose pegfilgrastim successfully mobilized an optimal number of CD34 + cells and was well tolerated. Pegfilgrastim could be an alternative option for PBSC mobilization in healthy volunteers. The trial was registered at www.clinicaltrials.gov (NCT03993639). - Type 1 Cryoglobulinemic Vasculitis Due to Monoclonal Gammopathy of Undetermined Significance Successfully Treated by Bortezomib Plus Dexamethasone.
Ryo Kikuchi; Masahiro Onozawa; Jun Nagai; Satomi Okada; Yuta Hasegawa; Hiroyuki Ohigashi; Shintaro Mitamura; Taku Maeda; Emi Takakuwa; Yuichiro Fujieda; Hideki Goto; Daigo Hashimoto; Yoshihiro Matsuno; Takanori Teshima
Internal medicine (Tokyo, Japan), 63, 4, 541, 545, 15 Feb. 2024, [Domestic magazines]
English, Scientific journal, Cryoglobulins are immunoglobulins that precipitate in cold conditions. Type I cryoglobulinemic vasculitis is associated with hematological malignancies. We herein report a case of steroid-resistant type 1 cryoglobulinemic vasculitis associated with monoclonal gammopathy of undetermined significance (MGUS) in a 47-year-old woman. By immunofixation of cryoglobulin, we found that the main component of cryoglobulin was the M protein due to MGUS, so treatment of MGUS was needed. Bortezomib+dexamethasone therapy resulted in a rapid decrease in cryoglobulin and improvement in the symptoms of cryoglobulinemic vasculitis. In refractory type I cryoglobulinemic vasculitis, treatment of the underlying gammaglobulinopathy should be considered. - R-Spondin1 protects gastric stem cells and mitigates gastric GVHD in allogeneic hematopoietic stem cell transplantation.
Eiko Hayase; Takahide Ara; Yumika Saito; Shuichiro Takahashi; Kosuke Yoshioka; Hiroyuki Ohigashi; Reiki Ogasawara; Emi Yokoyama; Tomohiro Yamakawa; Ko Ebata; Yuta Hasegawa; Kazuma Tomizuka; Takanori Teshima
Blood advances, 8, 3, 725, 731, 13 Feb. 2024, [International Magazine]
English, Scientific journal, Graft-versus-host disease (GVHD) is the major obstacle to performing allogeneic hematopoietic cell transplantation (allo-HCT). We and others have shown that intestinal stem cells are targeted in lower gastrointestinal GVHD. A leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5)-expressing gastric stem cells (GSCs) reside at the base of the gastric glands in mice. After experimental allo-HCT, Lgr5+ GSCs significantly decreased. Parietal cells, which underwent continuous renewal by GSCs, were injured in gastric GVHD, leading to failure of gastric acidification and aerobic bacterial overgrowth in the duodenum. Fate-mapping analysis demonstrated that administration of R-Spondin1 (R-Spo1) that binds to Lgr5 for 6 days in naïve mice significantly increased proliferating epithelial cells derived from Lgr5+ GSCs. R-Spo1 administered on days -3 to -1 and from days +1 to +3 of allo-HCT protected GSCs, leading to amelioration of gastric GVHD and restoration of gastric acidification, and suppression of aerobic bacterial overgrowth in the duodenum. In conclusion, Lgr5+ GSCs were targeted by gastric GVHD, resulting in disruption of the gastric homeostasis, whereas R-Spo1 protected Lgr5+ GSCs from GVHD and maintained homeostasis in the stomach. - 再発難治性びまん性大細胞型B細胞リンパ腫に対するCAR-T細胞療法後にpseudo-progressionを認めた1例
藤井 文彰; 千葉 雅尋; 橋田 里妙; 長谷川 祐太; 大東 寛幸; 安本 篤史; 後藤 秀樹; 山口 圭介; 小野澤 真弘; 橋本 大吾; 豊嶋 崇徳
臨床血液, 64, 12, 1523, 1524, (一社)日本血液学会-東京事務局, Dec. 2023
Japanese - Incidence and course of Epstein-Barr virus viremia after allogeneic hematopoietic stem cell transplant for adult-onset systemic chronic active Epstein-Barr virus disease.
Preeti Prerna M Vaswani; Masahiro Onozawa; Yuta Hasegawa; Hiroyuki Ohigashi; Takahide Ara; Toshihiro Matsukawa; Atsushi Yasumoto; Souichi Shiratori; Hideki Goto; Masao Nakagawa; Kaoru Kahata; Tomoyuki Endo; Daigo Hashimoto; Takanori Teshima
Bone marrow transplantation, 58, 12, 1397, 1399, Dec. 2023, [International Magazine]
English - Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT.
Hajime Senjo; Shinpei Harada; Shimpei I Kubota; Yuki Tanaka; Takahiro Tateno; Zixuan Zhang; Satomi Okada; Xuanzhong Chen; Ryo Kikuchi; Naoki Miyashita; Masahiro Onozawa; Hideki Goto; Tomoyuki Endo; Yuta Hasegawa; Hiroyuki Ohigashi; Takahide Ara; Yoshinori Hasegawa; Masaaki Murakami; Takanori Teshima; Daigo Hashimoto
Blood, 142, 5, 477, 492, 03 Aug. 2023, [International Magazine]
English, Scientific journal, Calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis is standard in allogeneic hematopoietic stem cell transplantation (HCT) but fails to induce long-term tolerance without chronic GVHD (cGVHD) in a considerable number of patients. In this study, we addressed this long-standing question in mouse models of HCT. After HCT, alloreactive donor T cells rapidly differentiated into PD-1+ TIGIT+ terminally exhausted T cells (terminal Tex). GVHD prophylaxis with cyclosporine (CSP) suppressed donor T-cell expression of TOX, a master regulator to promote differentiation of transitory exhausted T cells (transitory Tex), expressing both inhibitory receptors and effector molecules, into terminal Tex, and inhibited tolerance induction. Adoptive transfer of transitory Tex, but not terminal Tex, into secondary recipients developed cGVHD. Transitory Tex maintained alloreactivity and thus PD-1 blockade restored graft-versus-leukemia (GVL) activity of transitory Tex and not terminal Tex. In conclusion, CSP inhibits tolerance induction by suppressing the terminal exhaustion of donor T cells, while maintaining GVL effects to suppress leukemia relapse. - Subcutaneous Panniculitis-like T-cell Lymphoma Lacking Subcutaneous Tumor Mimicking Adult-onset Still's Disease.
Maria Tada; Shion Kachi; Masahiro Onozawa; Yuichiro Fujieda; Shota Yoshida; Yotaro Oki; Kazuro Kamada; Jun Nagai; Satomi Okada; Ryo Kikuchi; Ryo Hisada; Yuta Hasegawa; Hiroyuki Ohigashi; Hideki Goto; Daigo Hashimoto; Shinichi Nakazato; Yoshihiro Matsuno; Takanori Teshima; Tatsuya Atsumi
Internal medicine (Tokyo, Japan), 15 Mar. 2023, [Domestic magazines]
English, Scientific journal, We herein report a case of subcutaneous panniculitis-like T-cell lymphoma (SPTCL) resembling adult-onset Still's disease (AOSD). A 40-year-old woman presented with a fever, erythema, and painful subcutaneous nodules on the trunk. Laboratory data and a bone marrow analysis showed hemophagocytic syndrome. Although AOSD was suspected, based on a histopathological evaluation of the erythema, she was diagnosed with SPTCL. She was refractory to combination chemotherapy but achieved durable remission with cyclosporine monotherapy. Genetic testing revealed a homozygous HAVCR2 c.245A>G variant (rs184868814) that had caused NLRP3 inflammasome activation. SPTCL and AOSD share a pathogenesis in terms of NLRP3 inflammasome activation, so the clinical phenotype of SPTCL reasonably mimics AOSD. - Ultrasonographic monitoring of sinusoidal obstruction syndrome in patients treated with inotuzumab ozogamicin.
Takahito Iwai; Mutsumi Nishida; Junichi Sugita; Atsushi Yasumoto; Yuta Hasegawa; Tomoko Morimoto; Daishi Nakayama; Kohei Okada; Akio Mori; Takanori Teshima
International journal of hematology, 116, 6, 973, 975, Dec. 2022, [Domestic magazines]
English - Reactive granulopoiesis depends on T-cell production of IL-17A and neutropenia-associated alteration of gut microbiota.
Xuanzhong Chen; Daigo Hashimoto; Ko Ebata; Shuichiro Takahashi; Yu Shimizu; Ryuga Shinozaki; Yuta Hasegawa; Ryo Kikuchi; Hajime Senjo; Kazuki Yoneda; Zixuan Zhang; Shinpei Harada; Eiko Hayase; Takahide Ara; Hiroyuki Ohigashi; Yoichiro Iwakura; Kiminori Nakamura; Tokiyoshi Ayabe; Takanori Teshima
Proceedings of the National Academy of Sciences of the United States of America, 119, 48, e2211230119, 29 Nov. 2022, [International Magazine]
English, Scientific journal, Granulopoiesis in the bone marrow adjusts cellular output as demand for neutrophils changes. Reactive granulopoiesis is induced by profound neutropenia, but its mechanism remains to be clarified. We herein explored its mechanisms using mouse models of syngeneic hematopoietic stem cell transplantation (SCT) and 5-fluorouracil-induced neutropenia. After SCT, T cell production of IL-17A was up-regulated. Neutrophil recovery was significantly delayed in IL-17A-deficient or T cell-deficient RAG1-/- mice, and adoptive transfer of wild-type (WT) T cells facilitated neutrophil engraftment. Gut decontamination with oral antibiotics suppressed T cell production of IL-17A and impaired neutrophil recovery. Transplantation of fecal microbiota collected from neutropenic, not naive, mice promoted neutrophil recovery in these mice, suggesting that neutropenia-associated microbiota had a potential to stimulate reactive granulopoiesis. Our study uncovered a cross talk between gut microbiota and neutropenia after SCT and chemotherapy. - Antiretroviral therapy achieved metabolic complete remission of hepatic AIDS related Epstein-Barr virus-associated smooth muscle tumor.
Takahide Ara; Tomoyuki Endo; Hideki Goto; Kohei Kasahara; Yuta Hasegawa; Shota Yokoyama; Souichi Shiratori; Masao Nakagawa; Ken Kuwahara; Emi Takakuwa; Satoshi Hashino; Takanori Teshima
Antiviral therapy, 27, 5, 13596535221126828, 13596535221126828, Oct. 2022, [International Magazine]
English, Scientific journal, Epstein-Barr virus-associated smooth muscle tumor (EBV-SMT) is a rare mesenchymal tumor which occurs in immunocompromised patients. The immune status is an important factor in the treatment of EBV-SMTs, but the efficacy of antiretroviral therapy (ART) is not elucidated in acquired immune deficiency syndrome (AIDS) related EBV-SMTs. Here, we report the first successful case of a 29-year-old man with hepatic AIDS related EBV-SMT treated with ART solely. Positron emission tomography scan was useful for the evaluation of disease status. Recent advances in ART that enables to restore patient's immune status rapidly may change the treatment strategy in AIDS related EBV-SMT. - Ultrasonographic scoring system of late-onset sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic stem cell transplantation.
Mutsumi Nishida; Junichi Sugita; Takahito Iwai; Megumi Sato; Yusuke Kudo; Satomi Omotehara; Tatsunori Horie; Ryosuke Sakano; Yuta Hasegawa; Atsushi Yasumoto; Yuko Cho; Takanori Teshima
Bone marrow transplantation, 57, 8, 1338, 1340, Aug. 2022, [International Magazine]
English - Unilateral recurrent laryngeal nerve palsy detected by PET/CT in a patient with mediastinal T-cell lymphoblastic lymphoma.
Toru Miyajima; Yuta Hasegawa; Daigo Hashimoto; Takanori Teshima
International journal of hematology, 116, 1, 3, 4, Jul. 2022, [Domestic magazines]
English - Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation.
Zixuan Zhang; Yuta Hasegawa; Daigo Hashimoto; Hajime Senjo; Ryo Kikuchi; Xuanzhong Chen; Kazuki Yoneda; Tomoko Sekiguchi; Tatsuya Kawase; Hirofumi Tsuzuki; Takashi Ishio; Takahide Ara; Hiroyuki Ohigashi; Masao Nakagawa; Takanori Teshima
Bone marrow transplantation, 57, 5, 775, 780, May 2022, [Lead author], [International Magazine]
English, Scientific journal, Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a potentially curative therapy for FLT3 internal tandem duplication mutant (FLT3-ITD+) acute myeloid leukemia, but relapse rate is high. A recent study showed that sorafenib, a first generation FLT3 and multikinase inhibitor, enhanced graft-versus-leukemia (GVL) effects against FLT3-ITD+ leukemia via interleukin-15 (IL-15) production. However, it remains to be clarified whether this effect could be mediated by selective FLT3 inhibition. We investigated whether gilteritinib, a selective FLT3 inhibitor, could enhance GVL effects against FLT3-ITD transfected Ba/F3 leukemia (Ba/F3-FLT3-ITD) in mice. Oral administration of gilteritinib from day +5 to +14 after allo-SCT reduced expression of the co-inhibitory receptors PD-1 and TIGIT on donor CD8+ T cells and enhanced IL-15 expression in Ba/F3-FLT3-ITD. Bioluminescent imaging using luciferase-transfected Ba/F3-FLT3-ITD demonstrated that gilteritinib significantly suppressed leukemia expansion after allo-SCT, whereas it did not impact the morbidity or mortality of graft-versus-host disease (GVHD), resulting in significant improvement of overall survival. In conclusion, short-term administration of gilteritinib after allo-SCT enhanced GVL effects against FLT3-ITD+ leukemia without exacerbating GVHD. - HIV関連悪性リンパ腫の臨床的特徴
遠藤 知之; 後藤 秀樹; 荒 隆英; 長谷川 祐太; 横山 翔大; 高橋 承吾; 米田 和樹; 橋本 大吾; 橋野 聡; 豊嶋 崇徳
日本エイズ学会誌, 24, 1, 13, 20, (一社)日本エイズ学会, Feb. 2022
Japanese - [Bing-Neel syndrome successfully treated with tirabrutinib].
Keito Yokoyama; Hiroyuki Ohigashi; Toru Miyajima; Naoki Miyashita; Satomi Okada; Yuta Hasegawa; Junichi Sugita; Masahiro Onozawa; Daigo Hashimoto; Takanori Teshima
[Rinsho ketsueki] The Japanese journal of clinical hematology, 63, 8, 870, 875, 2022, [Domestic magazines]
Japanese, Scientific journal, Bing-Neel syndrome (BNS) is a rare disease manifestation of Waldenström's macroglobulinemia characterized by abnormal lymphoplasmacytoid cells infiltration of the central nervous system. In September 2019, a 46-year-old man presented to a previous hospital with hand tremors, nausea, and dysuria. Demyelination of cerebral white matter and the spinal cord was discovered using MRI. Steroid pulse therapy was used to treat inflammatory demyelinating disease, and it provided temporary relief, but the symptoms returned when the steroids were stopped. He was referred to our hospital in June 2020, for further evaluation with the possibility of hematological malignancy. BNS was diagnosed based on the presence of abnormal lymphoplasmacytoid cells in the bone marrow and cerebrospinal fluid (CSF), as well as the presence of the MYD88L265P mutation in the CSF specimen. In July 2020, BR (bendamustine, rituximab) therapy was administered, but it was ineffective. Oral administration of tirabrutinib, which was recently approved for WM, began in August 2020. He has achieved long-term remission and steroid withdrawal, with no notable side effects. This is the second report of successful treatment of BNS with tirabrutinib. More research is needed to confirm tirabrutinib's efficacy in the treatment of BNS. - Intestinal goblet cells protect against GVHD after allogeneic stem cell transplantation via Lypd8.
Takahide Ara; Daigo Hashimoto; Eiko Hayase; Clara Noizat; Ryo Kikuchi; Yuta Hasegawa; Kana Matsuda; Shoko Ono; Yoshihiro Matsuno; Ko Ebata; Reiki Ogasawara; Shuichiro Takahashi; Hiroyuki Ohigashi; Emi Yokoyama; Keitaro Matsuo; Junichi Sugita; Masahiro Onozawa; Ryu Okumura; Kiyoshi Takeda; Takanori Teshima
Science translational medicine, 12, 550, 01 Jul. 2020, [International Magazine]
English, Scientific journal, Graft-versus-host disease (GVHD) and infection are major obstacles to successful allogeneic hematopoietic stem cell transplantation (HSCT). Intestinal goblet cells form the mucus layers, which spatially segregate gut microbiota from host tissues. Although it is well known that goblet cell loss is one of the histologic features of GVHD, effects of their loss in pathophysiology of GVHD remain to be elucidated. In mouse models of allogeneic HSCT, goblet cells in the colon were significantly reduced, resulting in disruption of the inner mucus layer of the colon and increased bacterial translocation into colonic mucosa. Pretransplant administration of interleukin-25 (IL-25), a growth factor for goblet cells, protected goblet cells against GVHD, prevented bacterial translocation, reduced plasma concentrations of interferon-γ (IFN-γ) and IL-6, and ameliorated GVHD. The protective role of IL-25 was dependent on Lypd8, an antimicrobial molecule produced by enterocytes in the colon that suppresses motility of flagellated bacteria. In clinical colon biopsies, low numbers of goblet cells were significantly associated with severe intestinal GVHD, increased transplant-related mortality, and poor survival after HSCT. Goblet cell loss is associated with poor transplant outcome, and administration of IL-25 represents an adjunct therapeutic strategy for GVHD by protecting goblet cells. - Short-term KRP203 and posttransplant cyclophosphamide for graft-versus-host disease prophylaxis.
Emi Yokoyama; Daigo Hashimoto; Eiko Hayase; Takahide Ara; Reiki Ogasawara; Shuichiro Takahashi; Hiroyuki Ohigashi; Takahiro Tateno; Yuta Hasegawa; Xuanzhong Chen; Takanori Teshima
Bone marrow transplantation, 55, 4, 787, 795, Apr. 2020, [International Magazine]
English, Scientific journal, Posttransplant high-dose cyclophosphamide (PTCY) has been increasingly used as graft-versus-host disease (GVHD) prophylaxis after HLA-haploidentical or matched hematopoietic stem cell transplantation (SCT). However, PTCY alone is insufficient and requires additional immunosuppressants such as calcineurin inhibitors. In the current study, we evaluated effects of a novel GVHD prophylaxis with PTCY in combination with short-term KRP203, a selective agonist of sphingosine-1-phosphate receptor 1 that regulates egress of lymphocytes from the secondary lymphoid organs (SLOs) in mice. Short-term oral administration of KRP203 alone induced apoptosis of donor T cells in the SLOs and ameliorated GVHD. Administration of KRP203 significantly preserved graft-versus-leukemia effects compared to cyclosporin. A combination of KRP203 on days 0 to +4 and PTCY on day +3 synergistically suppressed donor T-cell migration into the intestine and skin, and ameliorated GVHD more potently than PTCY alone. A combination of short-term KRP203 and PTCY is a promising novel calcineurin-free GVHD prophylaxis in HLA-haploidentical SCT. - Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation.
Jonathan U Peled; Antonio L C Gomes; Sean M Devlin; Eric R Littmann; Ying Taur; Anthony D Sung; Daniela Weber; Daigo Hashimoto; Ann E Slingerland; John B Slingerland; Molly Maloy; Annelie G Clurman; Christoph K Stein-Thoeringer; Kate A Markey; Melissa D Docampo; Marina Burgos da Silva; Niloufer Khan; André Gessner; Julia A Messina; Kristi Romero; Meagan V Lew; Amy Bush; Lauren Bohannon; Daniel G Brereton; Emily Fontana; Luigi A Amoretti; Roberta J Wright; Gabriel K Armijo; Yusuke Shono; Míriam Sanchez-Escamilla; Nerea Castillo Flores; Ana Alarcon Tomas; Richard J Lin; Lucrecia Yáñez San Segundo; Gunjan L Shah; Christina Cho; Michael Scordo; Ioannis Politikos; Kasumi Hayasaka; Yuta Hasegawa; Boglarka Gyurkocza; Doris M Ponce; Juliet N Barker; Miguel-Angel Perales; Sergio A Giralt; Robert R Jenq; Takanori Teshima; Nelson J Chao; Ernst Holler; Joao B Xavier; Eric G Pamer; Marcel R M van den Brink
The New England journal of medicine, 382, 9, 822, 834, 27 Feb. 2020, [International Magazine]
English, Scientific journal, BACKGROUND: Relationships between microbiota composition and clinical outcomes after allogeneic hematopoietic-cell transplantation have been described in single-center studies. Geographic variations in the composition of human microbial communities and differences in clinical practices across institutions raise the question of whether these associations are generalizable. METHODS: The microbiota composition of fecal samples obtained from patients who were undergoing allogeneic hematopoietic-cell transplantation at four centers was profiled by means of 16S ribosomal RNA gene sequencing. In an observational study, we examined associations between microbiota diversity and mortality using Cox proportional-hazards analysis. For stratification of the cohorts into higher- and lower-diversity groups, the median diversity value that was observed at the study center in New York was used. In the analysis of independent cohorts, the New York center was cohort 1, and three centers in Germany, Japan, and North Carolina composed cohort 2. Cohort 1 and subgroups within it were analyzed for additional outcomes, including transplantation-related death. RESULTS: We profiled 8767 fecal samples obtained from 1362 patients undergoing allogeneic hematopoietic-cell transplantation at the four centers. We observed patterns of microbiota disruption characterized by loss of diversity and domination by single taxa. Higher diversity of intestinal microbiota was associated with a lower risk of death in independent cohorts (cohort 1: 104 deaths among 354 patients in the higher-diversity group vs. 136 deaths among 350 patients in the lower-diversity group; adjusted hazard ratio, 0.71; 95% confidence interval [CI], 0.55 to 0.92; cohort 2: 18 deaths among 87 patients in the higher-diversity group vs. 35 deaths among 92 patients in the lower-diversity group; adjusted hazard ratio, 0.49; 95% CI, 0.27 to 0.90). Subgroup analyses identified an association between lower intestinal diversity and higher risks of transplantation-related death and death attributable to graft-versus-host disease. Baseline samples obtained before transplantation already showed evidence of microbiome disruption, and lower diversity before transplantation was associated with poor survival. CONCLUSIONS: Patterns of microbiota disruption during allogeneic hematopoietic-cell transplantation were similar across transplantation centers and geographic locations; patterns were characterized by loss of diversity and domination by single taxa. Higher diversity of intestinal microbiota at the time of neutrophil engraftment was associated with lower mortality. (Funded by the National Cancer Institute and others.). - Myeloid differentiation factor 88 signaling in donor T cells accelerates graft-versus-host disease.
Satomi Matsuoka; Daigo Hashimoto; Masanori Kadowaki; Hiroyuki Ohigashi; Eiko Hayase; Emi Yokoyama; Yuta Hasegawa; Takahiro Tateno; Xuanzhong Chen; Kazutoshi Aoyama; Hideyo Oka; Masahiro Onozawa; Kiyoshi Takeda; Koichi Akashi; Takanori Teshima
Haematologica, 105, 1, 226, 234, Jan. 2020, [International Magazine]
English, Scientific journal, Myeloid differentiation factor 88 (MyD88) signaling has a crucial role in activation of both innate and adoptive immunity. MyD88 transduces signals via Toll-like receptor and interleukin-1 receptor superfamily to the NFκB pathway and inflammasome by forming a molecular complex with interleukin-1 receptor-associated kinase 4. The MyD88/interleukin-1 receptor-associated kinase 4 pathway plays an important role, not only in innate immunity, but also T-cell immunity; however, its role in donor T cells on the pathophysiology of graft-versus-host disease (GvHD) remains to be elucidated. We addressed this issue by using MyD88-deficient T cells in a mouse model of allogeneic hematopoietic stem cell transplantation (allo-SCT). While MyD88-deficient and wild-type T cells proliferated equivalently after transplantation, MyD88-deficient T cells demonstrated impaired survival and differentiation toward Th1, Tc1, and Th17, and induced less severe GvHD compared to wild-type T cells. Administration of interleukin-1 receptor-associated kinase 4 inhibitor PF-06650833 significantly ameliorated GvHD after allo-SCT. These results thus demonstrate that donor T-cell MyD88/interleukin-1 receptor-associated kinase 4 pathway is a novel therapeutic target against GvHD after allo-SCT. - Lactose drives Enterococcus expansion to promote graft-versus-host disease.
C K Stein-Thoeringer; K B Nichols; A Lazrak; M D Docampo; A E Slingerland; J B Slingerland; A G Clurman; G Armijo; A L C Gomes; Y Shono; A Staffas; M Burgos da Silva; S M Devlin; K A Markey; D Bajic; R Pinedo; A Tsakmaklis; E R Littmann; A Pastore; Y Taur; S Monette; M E Arcila; A J Pickard; M Maloy; R J Wright; L A Amoretti; E Fontana; D Pham; M A Jamal; D Weber; A D Sung; D Hashimoto; C Scheid; J B Xavier; J A Messina; K Romero; M Lew; A Bush; L Bohannon; K Hayasaka; Y Hasegawa; M J G T Vehreschild; J R Cross; D M Ponce; M A Perales; S A Giralt; R R Jenq; T Teshima; E Holler; N J Chao; E G Pamer; J U Peled; M R M van den Brink
Science (New York, N.Y.), 366, 6469, 1143, 1149, 29 Nov. 2019, [International Magazine]
English, Scientific journal, Disruption of intestinal microbial communities appears to underlie many human illnesses, but the mechanisms that promote this dysbiosis and its adverse consequences are poorly understood. In patients who received allogeneic hematopoietic cell transplantation (allo-HCT), we describe a high incidence of enterococcal expansion, which was associated with graft-versus-host disease (GVHD) and mortality. We found that Enterococcus also expands in the mouse gastrointestinal tract after allo-HCT and exacerbates disease severity in gnotobiotic models. Enterococcus growth is dependent on the disaccharide lactose, and dietary lactose depletion attenuates Enterococcus outgrowth and reduces the severity of GVHD in mice. Allo-HCT patients carrying lactose-nonabsorber genotypes showed compromised clearance of postantibiotic Enterococcus domination. We report lactose as a common nutrient that drives expansion of a commensal bacterium that exacerbates an intestinal and systemic inflammatory disease. - The association between the incidence of intestinal graft-vs-host disease and antibiotic use after allogeneic hematopoietic stem cell transplantation.
Daisuke Hidaka; Eiko Hayase; Souichi Shiratori; Yuta Hasegawa; Takashi Ishio; Takahiro Tateno; Kohei Okada; Hideki Goto; Junichi Sugita; Masahiro Onozawa; Masao Nakagawa; Kaoru Kahata; Tomoyuki Endo; Daigo Hashimoto; Takanori Teshima
Clinical transplantation, 32, 9, e13361, Sep. 2018, [International Magazine]
English, Scientific journal, Intestinal microbiota plays an important role in the regulation of allogeneic immune reaction after allogeneic hematopoietic stem cell transplantation (allo-SCT). Intestinal graft-vs-host disease (GVHD) is one of the major causes of mortality after allo-SCT and often complicated with intestinal dysbiosis. Recent studies suggest that antibiotic-induced dysbiosis is a risk factor for intestinal GVHD. We retrospectively evaluated the impacts of antibiotic use on the incidence of intestinal GVHD occurring before day 100 after allo-SCT. Among 213 patients who underwent allo-SCT, 200 patients achieving engraftment were analyzed. Antibiotics were classified into carbapenem, quinolone, penicillin, cephem, and glycopeptide. Among 128 patients who developed acute GVHD, intestinal GVHD developed in 36 patients. Patients with intestinal GVHD received significantly longer administration of carbapenem and glycopeptide compared to those without it in periengraftment period. In multivariate analysis, use of carbapenem for greater than 7 days was associated with an increased risk of intestinal GVHD. However, use of antibiotics for greater than 7 days was not associated with poor overall survival and high nonrelapse mortality. Long use of carbapenem in periengraftment period may be a risk for intestinal GVHD. Prospective studies are required to validate our findings.
- 輪注CD34細胞数がhaplo-PBSCT with PTCYの予後へ与える影響のRestricted cubic spline curveを用いた検討
原田 尚憲; 岡村 浩史; 諫田 淳也; 林 裕美; 稲本 賢弘; 福田 隆浩; 土岐 典子; 吉原 哲; 内田 直之; 長谷川 祐太; 森 康雄; 衛藤 徹也; 河北 敏郎; 西田 徹也; 鬼塚 真仁; 熱田 由子; 中前 博久, 日本血液学会学術集会, 87回, O3, 6, Oct. 2025
(一社)日本血液学会, English - FLT3阻害薬による移植片対白血病効果の促進
長谷川 祐太; 橋本 大吾, 日本造血・免疫細胞療法学会雑誌, 14, 4, 214, 223, Oct. 2025
(一社)日本造血・免疫細胞療法学会, Japanese - A case of secondary engraftment failure and autologous reconstituion due to HLH after allo-HSCT
杉村駿介; 三木康祐; 原田晋平; 長谷川祐太; 安本篤史; 後藤秀樹; 小野澤真弘; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 47th, 2025 - 大量失血を伴う手術時におけるレナカパビルの血中濃度の推移
遠藤知之; 田澤佑基; 遠藤知之; 田澤佑基; 新井崇之; 後藤秀樹; 松川敏大; 荒隆英; 長谷川祐太; 長井惇; 森木朝子; 高橋知希; 後藤了一; 後藤秀樹; 松川敏大; 荒隆英; 長谷川祐太; 長井惇; 森木朝子; 高橋知希; 後藤了一; 嶋村剛; 原貴信; 曽山明彦; 江口晋; 豊嶋崇徳; 江口晋; 豊嶋崇徳, 日本エイズ学会誌, 27, 4, 2025 - The Frequency of Blip and the Maintenance Rate of Target Not Detected (TND) in HIV-Positive Individuals Treated with a Two-Drug Regimen
遠藤知之; 遠藤知之; 後藤秀樹; 後藤秀樹; 松川敏大; 松川敏大; 荒隆英; 荒隆英; 長谷川祐太; 長谷川祐太; 須藤啓斗; 須藤啓斗; 宮島徹; 宮島徹; 長井惇; 長井惇; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 27, 2, 2025 - HIV感染者における悪性腫瘍の発生率と予後
松川敏大; 遠藤知之; 長谷川祐太; 高橋知希; 森木朝子; 長井惇; 後藤秀樹; 豊嶋崇徳; 松川敏大; 遠藤知之; 長谷川祐太; 高橋知希; 森木朝子; 長井惇; 後藤秀樹; 豊嶋崇徳; 遠藤知之, 日本エイズ学会誌, 27, 4, 2025 - GVHDによる腸幹細胞の炎症記憶は腸上皮の抗原提示とアポトーシスを促進する
宮島徹; 橋本大吾; 森木朝子; 小島圭祐; 塚本しほり; 一木朝絵; 齋藤祐美花; 李文ぎょく; 張紫せん; 原田晋平; 千丈創; 横井友樹; 長谷川祐太; 大東寛幸; 荒隆英; 中村公則; 谷口浩二; 豊嶋崇徳, 日本血液疾患免疫療法学会学術集会プログラム・抄録集, 17th, 2025 - Multiplex PCR on Cerebrospinal Fluid to Diagnose Central Nervous System Complications in AIDS Patients
松川敏大; 松川敏大; 遠藤知之; 遠藤知之; 遠藤知之; 森木朝子; 森木朝子; 長井惇; 長井惇; 宮島徹; 宮島徹; 長谷川祐太; 長谷川祐太; 荒隆英; 荒隆英; 後藤秀樹; 後藤秀樹; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 27, 3, 2025 - 骨髄移植後のGVHD治療中にVZV髄膜炎と中枢神経リンパ増殖性疾患を合併した1例
小宮かさね; 斎藤祐美花; 横山慶人; 原田晋平; 須藤啓斗; 長谷川祐太; 後藤秀樹; 小野澤真弘; 橋本大吾; 豊嶋崇徳, 臨床血液, 66, 11, 2025 - 低用量ST合剤による同種造血幹細胞移植後ニューモシスチス肺炎の予防効果についての検討
荒隆英; 遠藤知之; 長谷川祐太; 大東寛幸; 白鳥聡一; 橋本大吾; 豊嶋崇徳, 日本内科学会雑誌, 113, 2024 - A case of severe SOS after haploidentical HSCT rescued by HokUS-10-based early intervention
橋田里妙; 橋田里妙; 藤井文彰; 千丈創; 千葉雅尋; 長谷川祐太; 大東寛幸; 安本篤史; 後藤秀樹; 小野澤真弘; 表原里実; 西田睦; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 46th, 2024 - Impact of duration of response of prior therapy on therapeutic efficacy of CAR-T therapy in DLBCL
後藤秀樹; 荒隆英; 大東寛幸; 長谷川祐太; 千葉雅尋; 千丈創; 松川敏大; 安本篤史; 白鳥聡一; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 46th, 2024 - Low-molecular-weight heparin and the incidence of SOS/VOD during HSCT
白鳥聡一; 長谷川祐太; 大東寛幸; 荒隆英; 松川敏大; 安本篤史; 後藤秀樹; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 46th, 2024 - Retrospect Analysis of Sexually Transmitted Infection among People Living with HIV
松川敏大; 松川敏大; 遠藤知之; 遠藤知之; 長井惇; 長井惇; 宮島徹; 宮島徹; 須藤啓斗; 須藤啓斗; 長谷川祐太; 長谷川祐太; 荒隆英; 荒隆英; 後藤秀樹; 後藤秀樹; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 26, 3, 2024 - HIV感染合併血友病患者の運動機能評価およびリハビリテーションの有用性
遠藤知之; 遠藤知之; 渡部恵子; 渡部恵子; 原田裕子; 由利真; 千田尊子; 後藤秀樹; 後藤秀樹; 松川敏大; 松川敏大; 荒隆英; 荒隆英; 長谷川祐太; 長谷川祐太; 宮島徹; 宮島徹; 長井惇; 長井惇; 森木朝子; 森木朝子; 藤谷順子; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 26, 4, 2024 - ART療法が奏効した難治性サイトメガロウイルス腸炎の1例
長谷川祐太; 遠藤知之; 遠藤知之; 宮島徹; 宮島徹; 長井惇; 長井惇; 森木朝子; 森木朝子; 松川敏大; 松川敏大; 荒隆英; 荒隆英; 後藤秀樹; 後藤秀樹; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 26, 4, 2024 - Ruxolitinibが著効した難治性皮膚GVHD
長井惇; 一木朝絵; 菊池遼; 長谷川祐太; 大東寛幸; 後藤秀樹; 小野澤真弘; 橋本大吾; 豊嶋崇徳, 臨床血液, 65, 10, 2024 - 北海道ブロック「HIV/AIDS出張研修」12年間の実践報告
渡部恵子; 渡部恵子; センテノ(田村)恵子; センテノ(田村)恵子; 遠藤知之; 遠藤知之; 武内阿味; 武内阿味; 熊谷泰恵; 熊谷泰恵; 石田陽子; 石田陽子; 尾谷ゆか; 山口みなみ; 北村末季; 松川敏大; 松川敏大; 長谷川祐太; 長谷川祐太; 後藤秀樹; 後藤秀樹; 豊嶋崇徳; 豊嶋崇徳; 三宅亜矢; 三宅亜矢, 日本エイズ学会誌, 26, 4, 2024 - AIDS患者の髄液病原体網羅的解析を目的としたマルチプレックスPCRの有用性についての検討
松川敏大; 松川敏大; 遠藤知之; 遠藤知之; 森木朝子; 森木朝子; 長井惇; 長井惇; 宮島徹; 宮島徹; 長谷川祐太; 長谷川祐太; 荒隆英; 荒隆英; 後藤秀樹; 後藤秀樹; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 26, 4, 2024 - Lenalidomide長期内服中に急性赤白血病へ進展したdel(5q)単独の染色体異常を伴う骨髄異形成症候群
長井惇; 一木朝絵; 菊池遼; 長谷川祐太; 大東寛幸; 後藤秀樹; 小野澤真弘; 橋本大吾; 豊嶋崇徳, 臨床血液, 64, 7, 2023 - 2剤療法施行中のHIV陽性者におけるBlipおよびTND(Target Not Detected)維持率の検討
遠藤知之; 遠藤知之; 後藤秀樹; 後藤秀樹; 松川敏大; 松川敏大; 荒隆英; 荒隆英; 長谷川祐太; 長谷川祐太; 須藤啓斗; 須藤啓斗; 宮島徹; 宮島徹; 長井惇; 長井惇; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 25, 4, 2023 - HIV陽性者における性感染症の実態
松川敏大; 松川敏大; 遠藤知之; 遠藤知之; 長井惇; 長井惇; 宮島徹; 宮島徹; 須藤啓斗; 須藤啓斗; 長谷川祐太; 長谷川祐太; 荒隆英; 荒隆英; 後藤秀樹; 後藤秀樹; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 25, 4, 2023 - 血管内大細胞型B細胞性リンパ腫の初回治療中に発症したneurolymphomatosis
宮島徹; 大東寛幸; 横山慶人; 岡田怜; 長谷川祐太; 杉田純一; 小野澤真弘; 橋本大吾; 穴田麻眞子; 矢口裕章; 豊嶋崇徳, 臨床血液, 63, 7, 2022 - The incidence of Pneumocystis pneumonia after allogeneic hematopoietic stem cell transplantation
荒隆英; 長谷川祐太; 大東寛幸; 安本篤史; 白鳥聡一; 後藤秀樹; 杉田純一; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 44th, 2022 - Retrospective analysis of allo-SCT for adult T cell leukemia/lymphoma in single institution
荒隆英; 横山翔大; 長谷川祐太; 大東寛幸; 松川敏大; 安本篤史; 白鳥聡一; 後藤秀樹; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 45th, 2022 - CRP is a predictive marker of the antifebrile effect of tocilizumab on CRS during CAR-T cell therapy
横山翔大; 後藤秀樹; 荒隆英; 森祐斗; 長谷川祐太; 大東寛幸; 松川敏大; 安本篤史; 白鳥聡一; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 45th, 2022 - Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD+ leukemia after mouse HSCT
張紫せん; 長谷川祐太; 橋本大吾; 菊池遼; 陳げん仲; 米田和樹; 千丈創; 関口智子; 川瀬竜也; 續啓史; 石尾崇; 大東寛幸; 中川雅夫; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 43rd, 2021 - Multiplex PCR法を用いたAIDS患者における髄液病原体の網羅的解析
遠藤知之; 遠藤知之; 後藤秀樹; 後藤秀樹; 荒隆英; 荒隆英; 長谷川祐太; 横山翔大; 横山翔大; 高橋承吾; 高橋承吾; 米田和樹; 米田和樹; 小野澤真弘; 中川雅夫; 橋本大吾; 橋野聡; 橋野聡; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 23, 4, 2021 - 急性前立腺炎後に発症したFitz-HughCurtis症候群のMSMの一例
宮島徹; 大東寛幸; 横山慶人; 岡田怜; 長谷川祐太; 荒隆英; 荒隆英; 後藤秀樹; 後藤秀樹; 杉田純一; 小野澤真弘; 遠藤知之; 遠藤知之; 橋本大吾; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 23, 4, 2021 - 排尿障害と視神経炎を契機に診断されtirabrutinibが奏効したBing-Neel症候群の1例
横山慶人; 大東寛幸; 宮島徹; 岡田怜; 長谷川祐太; 杉田純一; 小野澤真弘; 橋本大吾; 豊嶋崇徳, 臨床血液, 62, 12, 2021 - Intestinal goblet cells play a protective role against GVHD via Lypd8 dependent manner after allogeneic hematopoietic stem cell transplantation
荒隆英; 橋本大吾; 早瀬英子; NOIZAT Clara; 菊池遼; 長谷川祐太; 奥村龍; 竹田潔; 豊嶋崇徳, 腸内細菌学雑誌, 34, 2, 2020 - HIV感染血友病患者の認知機能及び心理社会的問題の現状把握に関する研究
石田陽子; 石田陽子; 遠藤知之; 遠藤知之; 後藤秀樹; 後藤秀樹; 荒隆英; 荒隆英; 長谷川祐太; 長谷川祐太; 横山翔大; 横山翔大; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 22, 4, 2020 - HIV関連悪性リンパ腫の臨床的特徴の検討
遠藤知之; 遠藤知之; 後藤秀樹; 後藤秀樹; 荒隆英; 荒隆英; 長谷川祐太; 長谷川祐太; 横山翔大; 横山翔大; 橋本大吾; 橋野聡; 橋野聡; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 22, 4, 2020 - HIV感染症合併血友病患者における微小脳出血の経時的評価
遠藤知之; 遠藤知之; 後藤秀樹; 後藤秀樹; 荒隆英; 荒隆英; 長谷川祐太; 長谷川祐太; 横山翔大; 横浜翔大; 中川雅夫; 加畑馨; 橋本大吾; 橋野聡; 橋野聡; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 21, 4, 2019 - 同種造血幹細胞移植後にT細胞由来の異型リンパ球増加を伴い伝染性単核球症様症状を呈した再生不良性貧血
江端浩; 郎朗; 長谷川祐太; 早瀬英子; 白鳥聡一; 後藤秀樹; 中川雅夫; 遠藤知之; 豊嶋崇徳, 臨床血液, 59, 7, 2018 - 当院における急性骨髄性白血病に対する同種造血幹細胞移植の後方視的解析
長谷川祐太; 白鳥聡一; 早瀬英子; 岡田耕平; 後藤秀樹; 杉田純一; 小野澤真弘; 中川雅夫; 加畑馨; 橋本大吾; 遠藤知之; 近藤健; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 40th, 2017 - セフェピム脳症を来した末梢性T細胞リンパ腫の1例
長谷川祐太; 工藤彰彦; 郎朗; 江端浩; 早瀬英子; 白鳥聡一; 後藤秀樹; 中川雅夫; 加納崇裕; 遠藤知之; 豊嶋崇徳, 臨床血液, 58, 12, 2017
- 急性GVHDにおける腸管および胆管上皮幹細胞の炎症記憶の解明と新規治療法の開発
科学研究費助成事業
01 Apr. 2025 - 31 Mar. 2028
長谷川 祐太
日本学術振興会, 若手研究, 北海道大学, 25K19548
